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Abstract
The unbiased generation of specific and meaningful hypotheses from the deluge
of data generated by modern genomic methods remains a challenge. These datasets
require increasing level of expertise to analyze fully, and are often underutilized even
in the originating lab. It would be desirable to have a computational strategy that is
easy to implement, robust against outliers and missing data, and broadly applicable to
diverse experimental designs. In this dissertation, I present a set of ranksum
statistics-based analytical methods as a framework to extract testable hypotheses from
large and complex datasets. To illustrate its utility, this framework was applied to two
clinically important biological questions. In both instances, my method yielded novel
molecular mechanisms that were subsequently validated with both in vitro and in vivo
experiments. In the first study, gene expression profiles from multiple mouse models
of cardiac hypertrophy were analyzed to reveal a novel interaction between
transcription factors Nkx2-5 and Egr1, providing mechanistic insight into how Nkx2-5
haploinsufficiency leads to exacerbated cardiac hypertrophy and poor survival in
these mice. In the second study, thousands of microarray samples acquired from
public data repositories were analyzed to quantitatively define tissue-specific
expression pattern for every gene represented on a microarray platform. The
tissue-specific expression data was then used to identify novel transcriptional
regulators of brown fat gene expression program in adipocytes. The successful
application of the analytical framework in these examples, regardless of their differing
experimental design, highlights its adaptability in facilitating discoveries in a wide
array of biological problems.
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Chapter 1. Introduction
Obesity
Obesity is an epidemic
Obesity is a condition where excessive body fat accumulation negatively impacts
a person’s health. The most commonly used measure of obesity is based on the body
mass index (BMI), which is a ratio between a subject’s weight in kilograms and the
square of the subject’s height in meters, although an excess of body mass may not be
attributed to an excess of body fat in every case. The center for Disease Control and
Prevention defines a BMI between 25 and 30 as overweight, and a BMI greater than
30 as obese. The 2007-2008 National Health and Nutrition Examination Survey,
which sampled from the entire U.S. population 1, placed the prevalence of obesity at
33.8% and the combined prevalence of overweight and obesity at 68%. Since the
inception of the survey in the 1960’s, the prevalence of obesity has been on a steady
linear incline, and has since then doubled. In the same period, the prevalence of
obesity in children and adolescents has tripled to 16.9% in 2008. This is an alarming
trend since obese children tend to become obese adults. Obesity is a risk factor in a
plethora of diseases including coronary heart disease, hypertension, stroke, and type 2
diabetes, and is a major contributor to mortality. In the overweight and the obese, it is
estimated that each 5kg/m2 increase BMI translates to a 30% increase in all-cause
mortality 2. On average, a BMI increase from 24 to 32 leads to a loss of three years in
life expectancy. The health care cost attributed to obesity is estimated to be $147
billion per year in 2008 3.
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Causes and Treatments of Obesity
In animals, unspent energy intake is stored as triacylglycerols (TAGs) in the
adipose tissue as an evolutionary solution to the scarcity of food in the environment.
Obesity, therefore, is a consequence of both the unbalanced caloric homeostasis, and
the individual’s response to the unbalance as dictated by genetic and environmental
variables. Rare monogenic causes of obesity exist, such as defects in genes involved
in the leptin signaling pathway which regulates appetite. In the majority of cases,
obesity is a complex condition associated with multiple contributing factors. The
prevalence of obesity differs in subpopulations defined by ethnicity, gender, age, and
socio-economic status 1,4. Studies following twins reared apart reported only slightly
lowered correlation in BMI between the siblings compared to twins reared together,
suggesting strong genetic influences 5,6. A contrasting study, however, showed that
obesity can spread among non-related members in social networks, potentially
through shared environment and behavior 7. Recent papers showed the composition of
gut flora is altered in obese mice compared to the lean mice 8,9. While gut flora
composition and the BMI of the host have an interdependent and complex relationship,
these observations nevertheless open the possibility that obesity may be transmitted
between individuals in this fashion. Currently, options to treat obesity are limited.
Drugs which suppress appetite or fat absorption have questionable efficacy. Surgical
interventions are dangerous and available only to the most severe cases. Lifestyle
modification, which is the most effective and safe measure for the prevention and
treatment of obesity, is difficult to implement. Novel therapeutic strategies that
overcome the drawbacks in existing therapies are therefore desired.
White adipose tissue is a regulatory organ of metabolism
In obese individuals, the increase in adiposity occurs mainly in white adipose
2

tissues (WAT). In the body, WAT is distributed in discrete depots that are different
from each other in composition and properties 10,11. WAT consists mainly of white
adipocytes and little connective tissues. White adipocytes each feature a single large
lipid droplet where excess calories are stored as TAGs. In addition to being the energy
reservoir in the body, WAT is increasingly recognized as an endocrine organ. The
adipocytes produce a number of cytokines and chemokines, as well as other secreted
factors known as adipokines 12. Adipokines such as leptin and adiponectin are
regulators of energy intake and metabolism. Leptin, encoded by the ob gene, relays
satiety signal from WAT to the brain to suppress appetite 13. Adipokines have also
been implicated in disease processes. Adiponectin, for example, is protective against
type 2 diabetes 14. In obesity, adiposity increases to cause hypertrophy in the
adipocytes which precedes eventual adipocyte hyperplasia. The pathology of obesity,
however, is not merely the quantitative increase in WAT fat content. Another
hallmark of obesity is the dysregulation of secretory factors. The serum level of
adiponectin, for example, is inversely proportional to body fat percentage 14. Obese
WAT additionally up-regulates chemokines such CCL2 15. Increased secretion of
CCL2 leads to macrophage infiltration in WAT, resulting in the inflammation process
which is another qualitative changes occurring in obese WAT.
Brown fat as treatment for obesity
Brown adipose tissue (BAT) shares the ability to uptake lipids with WAT but is
structurally and functionally distinct. BAT acquires its appearance from the
abundance of mitochondria in brown adipocytes. Uncoupling protein 1 (Ucp1), a
BAT-specific protein, is uniquely expressed in these mitochondria to uncouple the
electron transport from ATP production to generate heat. In this regard, brown
adipocytes resemble cardiomyocytes in that both are metabolically active organ with
3

high mitochondrial content. The former converts chemical energy from fat into
thermo energy while the latter into mechanical work. Small mammals rely on BAT to
maintain thermo homeostasis as they are incapable of shivering. Human infants also
possess appreciable amount of BAT estimated at 5% of body weight, most of which is
lost by adulthood. Several recent discoveries have casted the BAT as a potential
therapy for obesity. First, PET scan on workers frequently exposed cold environment
showed increased BAT mass; suggesting the endogenous BAT may be activated in
adults. Second, dispersed brown fat clusters are found in the WAT depots in mice
subjected to cold-exposure or β-stimulation. Whether these ‘brite’ adipocytes
originate from of white adipocytes or circulating stem cells is undetermined, they are
distinct from brown adipocytes found in BAT depots. Third, recent works have
delineated much of the gene regulatory networks required to specify brown adipocyte
cell fate from the common progenitor cells shared with skeletal myocytes. In
particular, the transcription regulator Prdm16 is sufficient to drive the brown fat gene
program in a variety of cells. It is estimated that activation of half of the endogenous
BAT complement in a typical adult can expend energy equivalent to 4 kilogram of
body fat per year. Chemical or genetic interventions designed to activate endogenous
BAT or BAT-like clusters in WAT would thus be a powerful tool to combat the
obesity epidemic.
Heart Failure
Heart failure and intervention
Heart failure is a serious condition where the heart is unable to pump sufficient
amount of blood through the systemic circulation to meet the needs of the body. Heart
failure represents a major public health challenge both domestically and abroad.
Longitudinal data collected since the 1960’s have shown a steady increase in the
4

prevalence of heart failure, which is currently estimated to affect 5.7 million in the
U.S 16 and 22 million worldwide, despite continuing improvement in heart failure
therapeutics. Ironically, the increases in the prevalence of heart failure have been
attributed to advances in treatments for other cardiovascular diseases since these
patients can now survive with their conditions long enough to develop heart failure.
Current standard of care for treating heart failure patients includes use of ACE
inhibitor and β-blockers for those in the early stages of the disease. In the most severe
cases, surgical interventions such as implantation of left ventricular assist devices or
cardiac transplantations are needed. Despite their remarkable efficacy in prolonging
patients’ lives, modern heart failure treatments merely slow the progression of the
disease but cannot halt or reverse the pathogenic processes. As a result, prognosis for
heart failure patients remains poor. In the four decades following the first availability
of the aforementioned treatments in the 1960’s, the survival rate at five years after the
initial diagnosis only improved from 70% to 59% 17, which is still worse than most
forms of cancer 18. Although a large body of knowledge describing the molecular
basis of heart failure has accumulated, it is likely that other important pathogenic
pathways remain untargeted by the existing treatments. Research effort to identify
previously unknown pathogenic pathways is therefore critical in the development of
novel therapeutic strategies that would overcome limitations of current treatments for
heart failure.
Cardiac hypertrophy is an integral part in the pathogenesis of heart failure
Heart failure is a complex condition with multiple etiologies. Major risk factors
found in large epidemiological studies include male sex, age, diabetes, and obesity.
Heart failure is often the terminal progression of many cardiovascular conditions.
Hypertension, ischemic heart disease, cardiomyopathy, and valvular disease can all
5

lead to heart failure. Cardiac hypertrophy, or the enlargement of the heart, is a
condition frequently associated with these diseases, and is often an integral part of the
pathogenesis in the development to heart failure. The heart is a muscular organ with
90% of its mass made up by cardiomyoctyes. As in all muscle, the heart undergoes
hypertrophic response in reaction to increased load. Cardiac hypertrophy can be
divided into two categories depending on the underlying cause. Physiologic
hypertrophy follows stimuli such as exercise training and pregnancy, is reversible and
does not progress to heart failure. In contrast, pathologic hypertrophy results from
cardiac insults such myocardial infarction, cardiomyopathy, and hypertension. In
these cases the contractile property of the myocardium is impaired by the underlying
conditions, and the heart must compensate to maintain cardiac output via hypertrophic
response. Cardiac hypertrophy, in turn, leads to further diastolic and systolic
abnormalities that degrade cardiac output. As a result, pathologic hypertrophy does
not usually undergo remission and progresses into heart failure if left unmanaged.
Molecular basis of cardiac hypertrophy
Cardiac hypertrophy in response to pathological stimuli involves a complex
network of molecular sensors, signal transducers, transcription factors, and a host of
downstream target genes (reviewed in 19). Hypertrophic signals such as paracrine
growth factors and physical stretching of the myocytes are sensed by cell surface
receptors. These include integrin, a transducer of mechanical stress, endothelin-1
receptor, adrenergic receptor, EGF receptor, IGF1 receptor, and thyroid hormone
receptor. These receptors are targets of some of the most successful drugs to treat
heart failure such as ACE inhibitors and β-blockers. Nuclear receptors, such as the
thyroid hormone receptor, can translocate into the nucleus upon activation. Signals
from other receptors rely on signal transduction pathways to reach the transcription
6

factors in the nucleus. These pathways often begin with the disassociation of activated
g-proteins from the receptors. The g-proteins, in turn, pass the signal through a
network of kinases to the transcriptional and translational machineries to produce the
hypertrophic response. Intracellular calcium is another critical component of the
signal transduction leading to cardiac hypertrophy. Calcineurin, for example, is a
phosphatase that is activated by sustained increase in the intracellular calcium level
20,21

. When activated, calcineurin dephosporylates a number of proteins, including

transcription factor NFAT. In the nucleus, activated transcription regulators such as
NFAT, Mef2, and HDACs are recruited to modulate the expression of target genes
that induces various aspects of the hypertrophic response. These may include
switching from fatty acids to glucose as fuel 22, reactivation of fetal genes 23,
increased protein synthesis 24, increased apoptosis 25,26, and cell growth.
Relevant mouse models of cardiac hypertrophy
Transverse aortic constriction model (TAC) Since its invention in 199127,
transverse aortic constriction in rodents has been a widely adapted model of pressure
overload induced cardiac hypertrophy. In this model, a suture band is placed around
the transverse aorta using microsurgical techniques. The degree of aortic banding is
carefully controlled to produce a stenosis that results in a pressure gradient averaging
around 40mmHg, doubling the normal range, in the aorta proximal to the suture band
27

. This increases the afterload that the heart must pump against. The heart mitigates

the increased afterload either by increasing the ventricular wall thickness or by
increasing the ventricular diameter in accordance with the Law of LaPlace 28. TAC is
highly effective in inducing cardiac hypertrophy. Typically, differential gene
expressions in the TAC mice compared to that in the sham operated littermates can be
measured mere hours following the operation while increased cardiac mass can be
7

observed less than a week post operation. TAC, however, is not without drawbacks.
An experienced animal surgeon is required to maintain high consistency and low
mortality in TAC operations.
Calcineurin overexpression model Calcineurin transgenic (CnA-Tg) mice21
express a constitutively active form of calcineurin driven by a αMHC promoter,
thereby producing a high level of activated CnA protein in the heart. Calcineurin, as
described earlier, catalyzes the dephosphorylation of cytoplasmic NFAT in response
to sustained increases in intracellular calcium level. Dephosphorylated NFAT
translocates to the nucleus and activates a transcription program that is sufficient to
cause cardiac hypertrophy. CnA-Tg mice thus develop extensive cardiac hypertrophy
as early as five weeks of age. Similarly to the TAC model, the CnA overexpression
model is widely used in studies of cardiac hypertrophy. The CnA overexpression
model offers several advantages over the alternative. Since it is a genetic model, there
is a high degree of consistency in the cardiac hypertrophy developed in the CnA-Tg
mice. The extent of cardiac hypertrophy in these mice is often greater than what can
be achieved in surgical models. Lastly, there are no specialized staff and
instrumentation requirements to utilize the CnA-Tg mice in a study.
Role of Nkx2-5 in cardiac hypertrophy and heart failure
Nkx2-5 is a cardiac-specific transcription factor required for normal heart
development. Mutations of human NKX2-5 are associated with inherited congenital
heart defects (CHDs) 29,30. In mice, homozygous deletion of Nkx2-5 halts heart
development and is lethal to the embryo at E9-10. Heterozygous deletion of Nkx2-5
(Nkx2-5+/-) leads to a less severe phenotype. Nkx2-5+/- mice in C57 background
survive birth but carry a risk for conduction defects and CHDs 31. In the embryo,
Nkx2-5 expression first appears in the progenitor cells (in the heart field) specifying
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cardiac cell fate. Nkx2-5 expression persists through heart development and into the
postnatal adult heart 32. There is little literature describing the role Nkx2-5 plays in the
adult heart. Nkx2-5 is up-regulated in animal models of cardiac hypertrophy 33 and,
presumably, is involved in the development of the hypertrophic response.
Experimental evidence, however, does not converge on a unified paradigm of how
Nkx2-5 modifies the hypertrophic process. Transgenesis of dominant negative
Nkx2-5 in the adult mice leads to myocyte degeneration and increases the severity of
the detrimental effect of injected toxins on the heart 34,35. Similarly, conditional
deletion of Nkx2-5 in post-mitotic mouse hearts results in conduction and contraction
defects in the heart 36, although the severity of the phenotype decreases as the age of
the mice increases when the deletion is triggered. In contrast, overexpression of
wild-type Nkx2-5 using a αMHC promoter leads to the development of a conduction
defect and heart failure 37,38. These conflicting results suggest that the role for Nkx2-5
in the adult heart may be highly context-dependent. Further experiments where
Nkx2-5 level is minimally perturbed may be necessary to disambiguate the function
of Nkx2-5 in the postnatal heart.
Transcriptional regulation and expression profiling
Transcriptional is a fundamental mechanism underlying the causality of an
organism’s inherent genotype and its observed phenotype. At the simplest level,
transcription factors occupy transcription factor binding sequences (TFBSs) upstream
of a given gene to promote mRNA synthesis by basal transcriptional machinery.
Several mechanisms to modulate gene expression arise even within such a simple
model of transcription. Protein-DNA interactions between transcription factors and
TFBSs are governed by thermodynamics. As a result, variations in TFBS sequence
identity directly affect the dynamics of transcription factor-DNA complex formation.
9

Other properties of TFBSs, such as distance, orientation, and phase on the double
helix relative to a transcription start site can each influence interactions between
transcription factors and transcriptional machinery. In addition, transcription factors
may exert activating or suppressing effect. In mammalian cells, transcriptional
regulation is far more complex than the above model. A typical mammalian gene is
served by many transcriptional factors whose TFBSs are found anywhere from the
introns of the gene to hundreds of kilobases away from the transcriptional start.
Promoter/enhancer sequences can be covalently modified to vary their availability to
transcription factors. Transcription factors are also subject to positive or negative
regulation from upstream regulators, co-factors, or ligands, either by physical
interaction or chemical modification. Furthermore, nascent mRNAs can be stabilized
or degraded via covalent modification or microRNA regulation. Together these
mechanisms form a regulator network to ensure robust temporally- and
spatially-specific expression of genes at appropriate levels.

In normal development, as well as in pathogenesis of diseases, genes are
differentially regulated through modifications in transcriptional regulatory networks.
High-throughput experimental methods such as oligonucleotide microarray and, more
recently, parallel sequencing of cDNA (RNA-Seq), have been developed in the past
15 years to simultaneously quantify large number of mRNA transcripts. The
discipline of bioinformatics was created to manage datasets from these experiments
where the raw output has grown from mere megabytes, in the early generations of
microarrays, to hundreds of gigabytes in the latest RNA-Seq platform. As these
methods became accessible and increasingly ubiquitous in non-specialized
laboratories, a gap between the ability to generate data and the expertise to analyze
10

data has widened. Massive amount of data are deposited in open-access public data
repositories such as Gene Expression Omnibus but publications resulting from
meta-analyses of public datasets have been few in comparison. A computational
framework that is easy to implement, robust against outliers, insensitive to variations
in data processing practices by originating labs, and flexible to accommodate addition
of orthogonal data would promote utilization of high-throughput datasets and
maximize value of research investment.

11

Chapter 2: Gene discovery by non-parametric analysis of massively pooled,
public expression microarray data
Iuan-bor D. Chen1, Vinay K. Rathi1, Diana S. DeAndrade1, Maria Efimova1, Patrick
Y. Jay1,2
Departments of 1Pediatrics and 2Genetics
Washington University School of Medicine
Box 8208
660 South Euclid Avenue
St. Louis MO 63110
Correspondence to PYJ.
Phone: 314-362-2174
Fax: 314-286-2892
E-mail: jay_p@kids.wustl.edu

ABSTRACT
The vast trove of expression profiles in the Gene Expression Omnibus (GEO)
contains biological gems, but their mining poses formidable challenges not least
because data normalization is a complex problem. We present a simple,
non-parametric solution. Datasets based on the same microarray platform are
classified into two or more experimental groups. No pre-processsing of expression
data is necessary except for ranking probesets within each microarray in order of
signal intensity. The ranks of a probeset are then ranked across the microarrays that
comprise the experimental groups. Rank sum tests determine relative differences in
gene expression. Applied to the thousands of profiles of mouse tissues in GEO, the
method could define tissue-specific gene expression patterns across a wide dynamic
range. This permitted the accurate prediction of genes specifically relevant to the
function of an organ as well as the physiologic functions of an organ. Reasoning that
genes that perform a function are more specifically expressed in tissues that perform
12

the function than other tissues, we designed bioinformatic screens for transcription
factors that regulate brown adipocyte gene expression. Comparing the heart and
brown adipose tissue (BAT), the two most mitochondrial-rich tissues in the body, to
white adipose tissue (WAT), we predicted and validated a novel function for the
transcription factor Esrrg in the induction of BAT genes in white fat. Because the
heart and other tissues that express Esrrg do not express BAT genes, we hypothesized
that an adipocyte cofactor is required with Esrrg for BAT gene expression. By
comparing WAT and BAT to the heart, brain, kidney and skeletal muscle, we
discovered that an isoform of the transcription factor Srebf1 could induce BAT genes
in a muscle cell culture model. The results illustrate how our computational strategy
can make genomic data mining fruitful and more accessible to a larger community.
AUTHOR SUMMARY
Microarrays are a popular means to quantify the expression of thousands of
genes in a sample simultaneously. An experiment generates more data than an
investigator could ever interpret. The Gene Expression Omnibus (GEO) was hence
established so that others could glean additional insights from functional genomic
data. Data mining, however, typically requires a computational infrastructure that few
laboratories have because the preparation of heterogeneous datasets for conventional,
parametric statistical tests is complex. Given the huge number of GEO profiles for
virtually every cell and organ in the body, we show that a non-parametric statistical
approach is simpler and yet sufficiently powered to discover genes and biological
patterns. In proof-of-concept analyses we identified many genes known to be
specifically expressed in various organs and relevant to their function. Furthermore,
we could accurately predict the physiologic functions of an organ based on its list of
genes ranked by their specificity of expression. To prove the utility of our method
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prospectively, we designed bioinformatic screens and discovered two transcription
factors that regulate gene expression in brown fat. The more accessible computational
strategy can thus streamline the notoriously labor-intensive process of gene discovery
by harnessing the collective effort of the biomedical research community.
INTRODUCTION
Transcriptional profiling with microarrays is a popular means to explore gene
expression patterns. Consequently, a massive amount of data exists for virtually all
the tissues in the body. Submission of the data to public databases like the Gene
Expression Omnibus (GEO) is promoted so that secondary analyses can increase the
scientific return on a collectively huge investment.39 Compelling discoveries support
this intent,40-42 but typically only the contributors ever analyze the data.
Non-standardized data filtering, scaling and normalization can hinder the replication
of the original analytical results. Differences in sample preparation, hybridization,
scanning, and image processing can confound the reproducibility of an experiment,
which complicates the pooling of data across studies.43,44
All these issues are problematic because conventional statistical analyses of
microarray data are parametric. Data normalization, which can be vexing, is necessary
to assure a uniform probability distribution. We reasoned that a non-parametric
approach based on rank sum statistics could facilitate secondary analyses of
aggregated microarray datasets. Several properties of rank sum statistics make it ideal
to circumvent difficult problems with microarray data. First, the test is insensitive to
the underlying distribution of the observations, obviating the need for normalization.
Second, the results are robust against outliers and missing data because the test omits
some of the variance information contained in the datasets. The resulting loss of
statistical power can be offset by large sample sizes. Finally, rank sum statistics
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requires relatively little computational power and is amenable to parallelization.
To demonstrate the utility of the approach, we defined the tissue-specificity of
gene expression patterns across the genome for multiple organs by a meta-analysis of
GEO datasets based upon the Affymetrix Mouse Genome 430A 2.0 (MG430Av2)
microarray. In the past, genome-wide, tissue-specific gene expression patterns have
been determined by counting ESTs, which biases against rare transcripts.45,46 More
recently, tissue-specific gene expression patterns have been surveyed using a few
microarrays per organ, which limits the power to detect differences.47-51 In contrast,
the results of the rank sum method suggest that the approach is robust and sensitive
across a wide dynamic range of expression because the analysis draws from up to
hundreds of samples per organ and thousands for comparison between tissues.
A useful product of the method is the ranking of genes from most specifically to
most counter-specifically expressed in an organ. The term “counter-specific” is used
instead of “repressed” or “suppressed” so as not to imply an active regulatory
mechanism. Organs that perform a common function likely employ the same genes.
The genes are probably more specific to organs that perform the function than
elsewhere. This premise logically suggests bioinformatic screens for genes based on
threshold criteria for tissue specificity in various organs. The threshold criteria are
determined by set logic, prior knowledge, or both.
We thus developed bioinformatic screens for genes that regulate brown
adipocyte gene expression. Under normal conditions, uncoupling protein 1 (Ucp1) is
expressed predominantly in brown adipose tissue (BAT) but can be induced in the
white adipose tissue (WAT) of animals exposed to the cold.52-54 Ucp1 uncouples
mitochondrial oxidative phosphorylation to generate heat instead of ATP. BAT shares
the abilities with WAT for fat uptake and with cardiac and skeletal muscle for energy
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production via abundant mitochondria. The transcriptional coactivator, Prdm16, is
essential for the specification of BAT from a pre-myogenic precursor in the embryo
and the induction of BAT in adult WAT.55-59 Other genes are known to regulate BAT
gene expression.60 Additional genes might be found by comparing tissue-specific
gene expression patterns in WAT, BAT and mitochondrial-rich organs like the heart.
Through a series of bioinformatic screens and biologic experiments we identified
estrogen-related receptor gamma (Esrrg) and sterol regulatory element binding
transcription factor 1 (Srebf1) as transcriptional regulators of Ucp1 and other BAT
markers.
RESULTS
A non-parametric algorithm ranks genes by their tissue specificity of expression
Although expression microarrays are perceived to be insensitive to differences
among genes expressed at low levels, the non-parametric method could rank the
tissue-specificity of gene expression across a wide dynamic range. First, the
fluorescence rank of a gene, as represented by a probeset, was determined in order of
decreasing brightness for each microarray in the pooled dataset. Second, the
expression rank of a gene was determined by ranking the fluorescence ranks across all
the microarrays, which in turn were classified as being from the tissue of interest or
not. Third, we performed rank sum tests of the expression ranks for every gene in the
two microarray groups. The analysis generates a Z-score that lends itself to
genome-wide ranking of genes (Supplementary Table 2.1). Negative or positive
Z-scores correspond to genes specifically or counter-specifically expressed in the
tissue compared to all others. The tissue-specificity rank of each gene derives from
ranking the Z-scores. The analyses were performed on datasets from a single
microarray platform so that cross-platform differences in probeset performance would
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not confound the fluorescence rank relationships between genes (Fig. 2.1). Examples
of genes that are specific, counter-specific or neither in the heart follow.
The transcription factor Nkx2-5 and cardiac actin isoform Actc1 are expressed
almost exclusively in the heart.32,61 Consistent with their respectively low and high
levels of expression, their median fluorescence ranks are 3542 and 15 among the
45101 probesets in 175 profiles of postnatal murine hearts and 25449 and 25485 in
2270 non-heart arrays (P < 1 X 10-101 for both genes; Fig. 2.1b). From these data were
calculated the specificity ranks. Nkx2-5 and Actc1 are ranked 89 and 11 in the heart
but much lower in non-heart tissues (Fig. 2.1c).
At the opposite extreme, the fatty acid elongation protein Elovl5 is expressed at a
much lower level in the heart than elsewhere.62 The median fluorescence ranks of the
gene are 4485 and 1404 in the heart and non-heart arrays (P < 1 X 10-101; Fig. 2.1b).
The tissue-specificity rank of Elovl5 in the heart is 44970. The Z-score is large and
positive, consistent with counter-specific expression of the gene in the heart (Fig.
2.1c).
The ribosomal subunit Rplp0, also known as Arbp or 36B4, is expressed at
comparable levels in diverse tissues.63 The median fluorescence ranks of Rplp0 were
179 and 221 in the heart and non-heart arrays (P = 1; Fig. 2.1b). The gene has a
tissue-specificity Z-score near zero in most organs, reflecting its ubiquitous and
consistent level of its expression (Fig. 2.1c).
Rarely is a gene expressed exclusively in a single organ. A limited pattern of
expression can still be relatively tissue-specific. The algorithm provides a means to
judge relative specificity, as illustrated by the comparison of actin isoforms expressed
in skeletal muscle. Skeletal alpha-actin, Acta1, comprises ≥95% of the sarcomeric
actin in skeletal muscle, whereas Actc1 is a minor fraction.61 Acta1 and Actc1 have
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specificity ranks of 68 and 1031 in skeletal muscle, but Actc1 is still more specifically
expressed in muscle than other tissues except the heart (P < 1 x 10-34; Fig. 2.1c).
Genome-wide rankings of tissue-specific expression offer insight into gene and
organ function
The expression pattern of a gene can offer insight into its function. Several
observations suggest that our algorithm could offer similar insights. First, the
tissue-specificity rank of a gene in each organ appears to correlate well with a
function specific to the organ, as illustrated by the 10 transcription factors deemed
most specific in 15 tissues (Fig. 2.2). On average, mutation or knockout of ~6 of the
10 transcription factors is associated with a human disease or mouse phenotype
related to the function of the gene in the tissue. Of course, tissue-specific genes that
do not have a known mutant phenotype could still have a function. For example,
myelin transcription factor 1-like (Myt1l) is the third most brain-specific transcription
factor and with two other transcription factors can convert fibroblasts directly into
neurons (P = 4 x 10-274; Fig. 2.2, Supplementary Table 2.1). 64 The two, Pou3f2 and
Ascl1, are also highly brain-specific (P < 1 x 10-107 and < 1 x10-17. The least
significant statistic of the two probesets that represent each gene is presented.)
The repertoire of genes expressed by an organ determines its functions, which
suggests that the tissue-specificity ranks of genes could be adapted to predict organ
functions. Based on the Gene Ontology (GO) annotations for each gene, we
performed a rank sum analysis of biological processes according to their distribution
on the tissue-specificity rank list of an organ. Perusal of the analyses shows that the
specialized functions of an organ can be predicted from pooled microarray data (Fig.
2.3, Supplementary Table 2.2). Closer inspection suggests that additional insights may
be gleaned. For example, the testis and ovary produce gametes and sex hormones.
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Consistent with their shared functions, there is substantial overlap of the statistically
significant genes and biologic processes in the two gonadal organs (Fig. 2.2, 2.3). The
analyses can even suggest less obviously shared genes or functions. Genes and GO
terms related to immunity are expected for the spleen and thymus, but they are also
enriched in the intestine, lung and skin, thus highlighting their common function as a
barrier against pathogens (Fig. 2.3, Supplementary Tables 2.1 and 2.2).
Esrrg regulates brown adipocyte gene expression in white fat
The prior analyses of pooled microarray data revealed known tissue-specific
genes and biologic processes. We next tested predictive utility based upon the premise
that tissues that perform a common function utilize the same genes that are more
specifically expressed in said tissues. We developed a bioinformatic screen for genes
that could induce brown adipocyte gene expression in white adipose tissue while
considering two key facts. First, Prdm16 is a critical determinant of the brown fat
phenotype.59 Second, the heart and BAT are the most mitochondrial-rich tissues in the
body, whereas WAT is mitochondrial poor. We defined genes whose expression is
more or as specific to BAT and heart and more or as counter-specific to WAT than
Prdm16 in each tissue. The screen yielded 104 probesets, representing 97 unique
genes (Fig. 2.4a, Supplementary Table 2.3). The set is enriched for genes whose
products localize to the mitochondria (51% versus 9.3% of all genes on the
microarray, P = 3.07x10-16; Fig. 2.4b). In addition, 11% of the genes are regulated
directly or indirectly by the transcription factor Esrrg.65 which is also in the set,
whereas <1% of all represented genes are (P = 6.38x10-7). The increased mRNA
expression of Esrrg in BAT relative to WAT was verified by quantitative RT-PCR
(Fig. 2.4c).
These observations led us to examine the ability of Esrrg to induce mRNA
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markers of brown fat in OP9 cells, a white adipocyte cell culture model.66 Transiently
transfected Esrrg could up-regulate the expression of the BAT markers Ucp1, Cidea,
and Pcg-1α in differentiated OP9 adipocytes, while down-regulating the WAT marker
resistin (Fig. 2.4d, 2.4e). Esrrg had no effect in undifferentiated OP9 pre-adipocytes,
suggesting the requirement for an adipocyte-specific co-factor (Fig. 2.4d).
BAT gene expression can be induced in white adipocytes by the Pparg agonist
rosiglitazone.[34-36] Rosiglitazone similarly induced BAT markers as well as Esrrg
in differentiated OP9 adipocytes (Fig. 2.4f). To determine whether induction depends
upon Esrrg, we applied 4-hydroxytamoxifen (4-OHT), an Esrrg antagonist.67,68 The
drug suppressed the rosiglitazone-mediated induction of Ucp1 and Cidea (Fig. 2.4f).
Esrrg was likewise suppressed, which suggests either that Esrrg regulates its own
expression in a positive feedback loop or that 4-OHT acts on another target that
regulates Esrrg expression. Unfortunately, efforts to transfect OP9 cells with shRNA
constructs, as an alternative means to knock down Esrrg activity, were unsuccessful.
Mice subjected to the cold induce BAT genes in WAT. After housing for three
days at 4oC, Ucp1 and other BAT markers were up-regulated up to ten-fold in the
WAT. The up-regulation was abrogated by 4-OHT, which is consistent with a role for
Esrrg in the induction of BAT in WAT (Fig. 2.5a). Visual inspection during gross
dissection suggested that there was more intrascapular BAT after cold exposure, but
the expression of Ucp1 and other markers was only slightly upregulated or unchanged
(Fig. 2.5b). 4-OHT may not inhibit Ucp1 expression in BAT because Esrrg is
expressed an order of magnitude higher than in WAT (Fig. 2.4c). Treated mice
maintained normal body temperature while housed in the cold, consistent with the
maintenance of Ucp1 expression in BAT.
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Srebf1 induces brown adipocyte gene expression in cultured myoblasts
Esrrg induces BAT gene expression in adipocytes, but Esrrg is also highly
expressed in mitochondrial-rich tissues that have no Ucp1 (Fig. 2.6a.). White
adipocytes may possess a cofactor that renders them competent to express BAT
markers in the presence of Esrrg. A hypothetical cofactor should be expressed more
specifically in white and brown adipose tissue than mitochondrial-rich organs.
Prdm16 is probably not the cofactor, as the brain, heart and kidney express the gene,
albeit at lower levels than in BAT (Fig. 2.6a). A bioinformatic screen was designed
for genes that have negative tissue-specific Z-scores in WAT and BAT and positive
Z-scores in brain, heart, muscle and kidney. The screen yielded 614 annotated
probesets representing 564 unique genes, including 53 transcriptional regulators
(Supplementary Table 2.4). Srebf1 was selected for further analysis in a muscle cell
culture model because its expression pattern closely resembled the criteria for the
hypothesized Esrrg co-factor (Figure 2.5b). Of two alternatively spliced forms,
Srebp-1a and -1c, Srebp-1c was chosen for transfection because it is the predominant
isoform in white and brown adipocytes.69
Transfection of C2C12 myoblasts with Srebp-1c significantly induced the
expression of Ucp1, other BAT markers and Esrrg (Fig. 2.6c). If Srebp-1c and Esrrg
act together to induce brown adipocyte gene expression, then inhibition of Esrrg
should repress the induction in C2C12 cells by Srebp-1c. Consistent with this
hypothesis, 4-OHT abrogated the up-regulation of BAT markers by Srebp-1c, just as
it did in OP9 cells and in the WAT of cold-exposed mice. RNAi knockdown of Esrrg
likewise repressed the induction of BAT markers by Srebp-1c, whereas a control
shRNA had no effect. Srebp-1c had no effect on the expression of the
myocyte-specific marker tropomyosin 1 alpha (Tpm1) (Fig. 2.6c).
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DISCUSSION
Nature does not readily reveal the inner workings of life. Biologists expend great
effort on screens to discover genes and experiments to elaborate gene function. We
suggest that in some cases the total effort might be distributed across the larger
community. Expression microarrays have become a commonplace tool, whereas
statistical analyses seem increasingly complex. This asymmetry fosters the perception
that data mining is accessible only to laboratories that have substantial bioinformatics
support. Some complex problems do require sophisticated solutions, but a simple,
non-parametric statistical approach to massively pooled, heterogeneous datasets
uncovers a fertile middle ground. We apply the approach to provide a database that
ranks the tissue-specificity of gene expression in multiple organs and evidence for the
function of two transcription factors in BAT gene expression.
Microarray data are typically normalized to remove variation that is not of
biological interest. Normalization remains a challenging problem even when an
experiment is well-defined.41,70 Normalization of heterogeneous, pooled datasets is
immensely harder. Non-parametric statistics is suited for cases where the underlying
distribution of data is uncertain and when large sample sizes are available. Despite the
greater statistical power of parametric tests, rank sum tests applied to aggregated GEO
datasets could clearly define tissue-specific gene expression patterns in a variety of
organs. The large sample sizes afforded by GEO ensure the robustness of analyses
against random and technical variation. Genes are detected across a wide dynamic
range of expression, as shown by the identification of low-expressed transcription
factors with organ-specific functions. Higher order biological patterns hidden in GEO
are also detectable, as shown by the prediction of the specialized functions of organs.
In addition to demonstrating the utility of the strategy, the tissue-specificity rank
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lists for multiple organs may be useful in their own regard. For example, given a
chromosomal interval determined by genetic linkage or association, one may ask
whether any gene within the locus is expressed in an organ relevant to the phenotype.
More broadly, the statistical strategy should be amenable to any biological question
that can be addressed by comparison of microarray samples classified into two or
more groups. The resulting list of ranked genes can inform experimental priorities, as
shown by implication of Esrrg and Srebf1 in BAT gene expression.
A good screen should be simple and fruitful. Mechanistic questions remain
regarding the role of Esrrg and Srebf1 in the determination of the BAT phenotype, but
the experimental results prospectively demonstrate the yield of a bioinformatic
strategy based upon simple statistical analyses of public microarray data. Other genes
that were identified in the same screens as Esrrg and Srebf1 likely have relevant
functions. For example, Pgc-1α was identified in the screen for genes specific to the
heart and BAT but not WAT. Originally cloned from a brown fat cDNA library,
Pgc-1α is essential to mitochondrial biogenesis and BAT thermogenesis.71,72 In the
screen for genes specific to BAT and WAT but not other mitochondrial-rich tissues,
Tle3 was represented by two probesets along with Srebf1 and 51 other transcriptional
regulators. Tle3 was recently discovered in a screen of 18,292 cDNA vectors to
co-regulate adipogenesis with Pparg. Interestingly, Cebpa, a positive control in the
cDNA screen, was likewise identified in the bioinformatic screen.73
Obviously, no screen is perfect or all-encompassing. Sensitivity is limited by the
design of the screen. For example, the present analyses would not identify
ubiquitously expressed genes that regulate BAT gene expression. Specificity is a
concern too, but seemingly false positive results could be genes that have functions
implicitly included in a bioinformatic screen. Hence, the screen that yielded Esrrg
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captured genes that perform mitochondrial functions, which is consistent with the
high abundance of mitochondria in the heart and BAT. Despite the limitations, we
suggest that they are outweighed by the relative simplicity of the non-parametric
statistical approach and the consequent ease of extracting biological insights from
GEO. Tapping into the collective labor that populated the public database, a research
team could spread the herculean effort otherwise expended by them to elucidate a
gene or biological function.
METHODS
Data acquisition and processing
Via the GEO interface
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL1261), we downloaded
4983 Affymetrix Mouse Genome 430A 2.0 microarray datasets (MG430Av2;
Affymetrix, Inc., Santa Clara, CA; GEO platform accession GPL1261) in SOFT
format. A custom Perl script parsed the SOFT file and assigned a source organ to each
sample by matching a set of keywords for each organ to the sample source and the
submitter’s description fields. Computer-generated organ designations were manually
confirmed by IDC and PYJ. An overview of the microarray collection is shown (Fig.
2.1a). Of the 4983 microarrays in the collection, 2538 were excluded because the
biological samples were of unknown origin, fetal in origin, cultured cell lines, or
derivatized, e.g., a subpopulation of cells purified from an organ, resulting in a set of
2445 microarray datasets used in the tissue-specific gene expression analysis.
Probeset annotations (release 30) in .csv format were downloaded from the
Affymetrix NetAffx portal (www.affymetrix.com).
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Statistical algorithm
To detect differential gene expression between two groups consisting of a total of
m samples run on the same microarray platform, the meta-analysis algorithm first
converted absolute fluorescence values (i.e., VALUE column from the SOFT
formatted file) within each microarray sample into fluorescence ranks from 1 to n in
order of decreasing brightness, where n is the number of probesets represented on the
microarray (Fig. 2.1b). For samples with fewer than n fluorescence values reported,
the fluorescence ranks were scaled to range from 1 to n. For each of the n probesets,
the algorithm ranked the fluorescence rank values in descending order across the m
samples to determine expression ranks from 1 to m. A Wilcoxon rank sum test was
then applied to the expression rank values for the two groups being compared to
generate a Z-score, where a greater absolute Z-score represents more significant
differential expression between the two groups being compared. The sign of the
Z-score indicates which of the two groups has higher relative expression of the gene
as measured by the probeset. To assess tissue-specific expression, the samples from
the tissue of interest are compared to all others that are not. The tissue-specificity rank
of a gene was determined by ranking Z-scores generated by the rank sum tests from
the most negative to the most positive; a lower Z-score reflects greater tissue
specificity.
Gene Ontology analysis
Gene Ontology (GO) biological process terms associated with the probesets on
the Affymetrix MG430Av2 microarray were extracted from the probeset annotation
file. The tissue-specificity of a given GO term was determined by a rank sum test.
Probesets from a tissue-specificity rank list for a particular organ were divided into
two groups that were either annotated with the given GO term or not. The enrichment
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of the annotated group toward the top or the bottom of the ranklist was described by
the rank sum test Z-score and p-value. The enrichment of GO terms in a set of
probesets identified in the bioinformatic screen for potential brown adipose tissue
regulators was evaluated with GeneMerge.74 Significance thresholds were set at a
false discovery rate of 5%.
Cell culture
The OP9 pre-adipocyte cell line was a generous gift from Dr. Paul Hruz
(Washington University School of Medicine, St. Louis, MO). The OP9 culture was
maintained and differentiated into adipocyte-like cells as previously described.66 The
OP9 pre-adipocytes were transfected using Optifect (Invitrogen, Carlsbad, CA) as per
the manufacturer’s instructions. Transfected OP9 adipocytes were cultured for an
additional three days after transfection and differentiation before harvesting. In
pharmacologic experiments, differentiated OP9 cells were incubated with the Pparg
agonist rosiglitazone (10 µM in DMSO, Sigma Aldrich, St. Louis, MO) and/or Esrrg
antagonist 4-hydroxytamoxifen (4-OHT; 10 µM in DMSO, Sigma Aldrich) for 48
hours before harvesting.
The C2C12 skeletal myoblast cell line was purchased from and maintained
according to the protocol supplied by ATCC (Manassas, VA). C2C12 cells were
transfected using Lipofectamine 2000 (Invitrogen) per the manufacturer’s instructions.
The cells were maintained for an additional 36 hours after transient transfection
before harvesting. In pharmacologic experiments, C2C12 cells were incubated with
4-OHT at 10 µM for 48 hours before harvesting.
Expression Plasmids
A pcDNA3.1(-)-Met-Esrrg expression construct was a gift from Daniel Kelly
(Burnham Institute for Medical Research, Lake Nona, FL). A pSV SPORT Srebp-1c
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expression construct was purchased from Addgene (Cambridge, MA). Esrrg targeting
(Target gene 26381) and control shRNA constructs from the RNAi Consortium
library (Broad Institute, Cambridge, MA) were obtained via The Genome Institute at
Washington University and the Children's Discovery Institute (St. Louis, MO).
Animal Studies
12-week-old female FVB/N mice were treated with intraperitoneal injection of
4-OHT (25 mg/mL in sunflower seed oil and 10% DMSO) or vehicle once daily at 0.1
mg/g/day. The mice were placed in a 4°C room six hours after the first injection. They
received food and water ad libitum. The core temperature of each mouse was
measured twice daily with a K-type thermocouple probe digital thermometer.
Abdominal white adipose tissue and intrascapular brown adipose tissue were
harvested after 72 hours of cold exposure. The experiments were approved by the
animal studies committee at Washington University School of Medicine.
RNA Isolation and Quantitative PCR
RNA was isolated from the tissue samples using Trizol (Invitrogen), according to
the manufacturer’s protocol. The precipitated RNA was resuspended in 175 µL of
RNA lysis buffer from the SV Total RNA Isolation Kit (Promega, Madison, WI) and
purified according to the manufacturer’s protocol. Total RNA from cultured cells
were isolated with SV Total RNA Isolation Kit only. cDNA was synthesized from 2.5
µg of total RNA using SuperScript VILO cDNA Synthesis Kit (Invitrogen) according
to manufacturer’s protocol.
Quantitative PCR of cDNA was performed in Cycler iQ system (Bio-Rad,
Hercules, CA) or Mx3005P QPCR System (Stratagene, Santa Clara, CA) in a 40 µL
reaction containing iQ SYBR Green Supermix (Bio-Rad) and PCR primers at a final
concentration of 200 nM. Primer sequences were designed with the PerlPrimer or
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obtained from PrimerBank.75,76 Primers were purchased from Sigma Aldrich or
Integrated DNA Technologies (Coralville, IA). The primer sequences are available in
the supplemental methods. Relative mRNA expression was calculated using the
ΔΔ-Ct method and normalized to Hprt1.
Student’s t-tests were used to compare groups in the qPCR studies. The data are
reported as mean ± s.e.m.
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Figure 2.1: A non-parametric statistical approach defines tissue-specific gene
expression patterns from massively pooled microarray datasets. (a) The tissue of
origin for the 4983 Affymetrix MG430Av2 microarray samples downloaded from
GEO and the number of samples for each tissue used in subsequent analyses are
shown. (b) A gene, represented by a probeset, is ranked by its fluorescence intensity
on a microarray for every sample in the collection. Top, fluorescence ranks for the
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cardiac-specific transcription factor Nkx2-5 (red tracing) and cardiac actin isoform
Actc1 (orange) are shown. Their fluorescence ranks are generally higher in cardiac
microarrays, consistent with their cardiac specificity. Bottom, fluorescence ranks for
the ribosomal subunit Rplp0 (green) and fatty acid elongation protein Elovl5 (blue)
are shown. The fluorescence ranks of Rplp0 are equivalent in cardiac and non-cardiac
samples, which is consistent with its known uniform expression in diverse tissues and
its use as a reference or housekeeping gene for mRNA quantification. Elovl5 is
expressed at low levels in the heart and likewise has generally lower fluorescence
ranks in cardiac samples. The fluorescence ranks are plotted in reverse logarithmic
scale. The non-cardiac portion of the tracings is compressed horizontally to facilitate
the interpretation of the plots. (c) The tissue-specificity ranks of Nkx2-5, Actc1, Rplp0,
and Elovl5 are shown for various organs in reverse logarithmic scale; higher points
denote greater specificity.
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Figure 2.2: The ten most specifically expressed transcription factors in 15 different
tissues are listed. If several probesets represent transcription factor, the most
significant probeset is shown. Genes were identified as transcription factors if their
associated Gene Ontology terms included “0006355 regulation of transcription,
DNA-dependent” or “0006350 transcription” and “0003677 DNA binding”. The
official gene symbols and p-values derived from our tissue specificity rank sum
analysis are shown. Filled boxes indicate the existence of human (H) or mouse (M)
mutant phenotypes related to the function of the transcription factor in the organ.
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Figure 2.3: The function of an organ can be predicted from the GO biological process
terms assigned to genes ranked by their specificity of expression in the organ.
Representative, significant functions for a number of organs are shown here with their
GO accession number and P-value. Significance thresholds were defined by setting a
false discovery rate to 5%. The full lists of GO terms are provided in the
Supplementary Table 2.2.
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Figure 2.4: Esrrg induces BAT gene expression program in white adipocytes. (a)
Schematic representation of the bioinformatic screen. Left, the tissue specificity
scores in BAT, WAT, and the heart are plotted for all 45101 probesets (gray)
represented on the MG430Av2 microarray. The probesets (blue) that are more or as
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specific to BAT and the heart and more or as counter-specific to WAT than Prdm16
were identified. Right, the probesets are shown with Prdm16, Esrrg, and
Esrrg-regulated genes in green, red, and yellow, respectively. (b) The subset is
significantly enriched for mitochondrial genes and genes regulated by Esrrg.
Significance thresholds were set by a false discovery rate of 5%. (c) Quantitative
RT-PCR analysis of Esrrg mRNA in murine BAT and WAT (*, P = 0.023; n = 4). (d)
Esrrg induces Ucp1 mRNA expression in differentiated but not undifferentiated OP9
cells; GFP control transfections are shown for comparison (*, P < 0.05; n = 3). (e)
Essrg induces additional BAT markers, Cidea, Pgc-1α, Pparg, and Prdm16, and
suppresses the WAT marker Resistin in differentiated OP9 cells. (*, P < 0.05; n = 3).
(f) The Pparg agonist rosiglitazone induces BAT markers in differentiated OP9 cells,
an effect that is suppressed by the Esrrg antagonist 4-hydroxytamoxifen (4-OHT).
Data are reported relative to vehicle-treated cells. (*, P < 0.05 versus vehicle-treated
cells; #, P < 0.05 versus rosiglitazone-treated cells; n = 4). Error bars indicate s.e.m.
BP, biological process. CC, cellular component. MF, molecular function. ND, not
detected.
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Figure 2.5: (a) Exposure of mice to the cold induces brown adipocyte gene
expression in WAT. The Esrrg antagonist 4-OHT suppressed the effect of cold
exposure. (b) 4-OHT did not suppress the cold-induced induction of Ucp1 in BAT
possibly because Esrrg is expressed at higher levels in BAT than WAT. Fold changes
are stated relative to the WAT or BAT of vehicle-treated mice housed at room
temperature. (*, P < 0.05 with respect to vehicle treated mice at room temperature; #,
P < 0.05 with respect to vehicle-treated mice exposed to the cold.) n = 6 animals per
group. Error bars indicate s.e.m.
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Figure 2.6: (a) Ucp1 is specifically expressed in BAT, whereas Prdm16 and Esrrg are
expressed in various other tissues, suggesting that an adipocyte cofactor is necessary
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for Esrrg to induce the brown adipocyte gene expression program (n = 4; ND, not
detected). (b) Srebf1 is more highly expressed in the liver, WAT and BAT than other
mitochondrial rich tissues (n = 4). (c) Srebp-1c induces the brown adipocyte gene
expression program in C2C12 myoblasts. Induction depends upon endogenous Esrrg,
as shown by inhibition or knockdown of Esrrg by 4-OHT or shRNA, respectively. A
lacZ control shRNA construct had no effect on Srebp-1c induction of brown fat
markers. The measurements are normalized to GFP-transfected cells. Transfections
were performed in triplicate. Error bars indicate s.e.m. (*, P < 0.05 compared to
GFP-transfected controls; #, P < 0.05 compared to Srebp-1c-transfected cells; n = 3).
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Background: Nkx2-5 is critical in fetal heart development but the postnatal role for
Nkx2-5 is less well known.
Results: Nkx2-5+/- mice exhibit aggravated pathology and poor survival in cardiac
hypertrophy.
Conclusion: Nkx2-5 interacts with hypertrophy mediator Egr1 and suppresses the
activation of Egr1 gene targets in cardiac hypertrophy.
Significance: A novel pathogenic mechanism in cardiac hypertrophy is identified,
demonstrating the utility of the bioinformatics presented.

SUMMARY
The cardiac-specific transcription factor Nkx2-5 is critical in embryonic heart
development. In mice, Nkx2-5 null mutation is embryonically lethal. Nkx2-5
heterozygous (Nkx2-5+/-) animals survive birth but have high rate of congenital heart
defects. The postnatal role for Nkx2-5 is less well understood. The present study aims
to delineate how Nkx2-5 functions in the adult heart by characterizing Nkx2-5+/- mice
in the context of pathological cardiac hypertrophy. Nkx2-5+/- pups born without heart
malformations were otherwise healthy and indistinguishable from wild-type
littermates. In these mice, hypertrophic stimuli such as calcineurin overexpression
(CnA-Tg) and transverse aortic constriction led to exacerbated hypertrophic responses
and poor survival compared with wild-type littermates. Computational analyses in the
proximal promoters of genes differentially regulated both in cardiac hypertrophy and
Nkx2-5 haploinsufficiency under hypertrophic conditions revealed an enrichment of
transcription factor binding sites for hypertrophy mediator early growth response 1
(Egr1). In vitro, Nkx2-5 physically interacted with Egr1 and Egr1-specific suppressor
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NGFI-A binding protein 1 (Nab1) to down-regulate Egr1-dependent transcriptional
activation. NGFI-A binding protein 2 (Nab2) is a Nab1 paralog and a target of this
regulation. An increase in Nab2 level reduced Nkx2-5- and Nab1-dependent
suppression of Egr1 activity. In vivo, decreased Nab2 expression in Nab2+/-/CnA-Tg
mice attenuated the hypertrophic response and improved survival in comparison to
Nab2 WT/CnA-Tg littermates. Thus, Nkx2-5 can modulate cardiac hypertrophy
through suppressing Egr1-dependent transcriptional activation in target genes such as
Nab2. The computational method presented here is useful for discovering
transcriptional regulatory pathways in physiological or pathological processes
involving differential gene regulation.
INTRODUCTION
Pathological cardiac hypertrophy is an important sequela in heart conditions of
diverse etiologies. In response to detrimental stimuli such as pressure overload, gene
programs are activated in the heart to up-regulate protein synthesis, leading to
increases in cardiomyocyte volume and cardiac mass. Cardiac hypertrophy is initially
a compensatory mechanism but can progress to heart failure over time if left
unmitigated 77. Transcriptional regulation is a critical mechanism in the pathogenesis
of cardiac hypertrophy. The re-activation of genes normally restricted to the
developing fetal heart, such as atrial natriuretic factor (ANF) and β-myosin heavy
chain (Myh7), is a universal hallmark in pathological hypertrophic process 78. Nkx2-5
is a cardiac-specific transcription factor with essential functions in cardiac
development. Nkx2-5 has been shown to drive the expression of ANF, Myh7, and
other cardiac hypertrophy marker genes 79, and is itself up-regulated in
adrenergic-induced cardiac hypertrophy 33. In a study of heterozygous human NKX2-5
mutation, several individuals haploinsufficient for Nkx2-5 presented with idiopathic
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left ventricular hypertrophy 30. This led us to wonder whether the reduced NKX2-5
level in affected individuals might lead to hypersensitivity to biomechanical stimuli
that induce cardiac hypertrophy. We tested this hypothesis by characterizing the
cardiac hypertrophic response in Nkx2-5+/- mice challenged with pathological surgical
and genetic stimuli.
Nkx2-5 exhibits a gene-dosage dependent developmental phenotype in the
embryonic heart. In mice, a germline, homozygous knockout mutation in Nkx2-5
leads to the arrest of cardiac development at the looped heart tube stage 79,80 and is
embryonically lethal. Mice with a heterozygous deletion of Nkx2-5 (Nkx2-5+/-) survive
birth, but the mutation is associated with an increased incidence of congenital heart
defects (CHDs) such as atrial and ventricular septal defects (ASDs and VSDs) 31.
Similarly, heterozygous mutations of NKX2-5 are associated with anatomic and
conduction defects in human patients 30,81. Nkx2-5 expression persists into adulthood
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, but the postnatal role of Nkx2-5 is less well defined. Because the genetic deletion

of Nkx2-5 is embryonic lethal, alternative experimental strategies have been employed
to elucidate the postnatal functions of Nkx2-5 34,82. Conditional deletion of Nkx2-5
leads to degeneration in the conduction and contractile functions in the perinatal
mouse model 36,82, suggesting that Nkx2-5 may be involved in the maintenance of
cardiac function in healthy cardiomyocytes. The functional role of Nkx2-5 in
pathological conditions is equally ambiguous. Overexpression studies of Nkx2-5 in
mice have yielded mixed results, ranging from a hypertrophy-free phenotype to heart
failure as early as 4 months of age 37,38. Transgenic mice expressing a dominant
negative form of Nkx2-5, however, demonstrate both cardiac conduction defects and
increased cardiac apoptosis when challenged with doxorubicin 34,35, suggesting that
Nkx2-5 may be protective in the adult heart. The available experimental data thus
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point to the involvement of Nkx2-5 in the pathogenesis of cardiac hypertrophy,
although the precise role of Nkx2-5 in the development of cardiac hypertrophy was
not examined directly.
The Nkx2-5+/- mice expresses half the normal levels of Nkx2-5 mRNA and
protein 81, which is a minimal perturbance in comparison to the alteration of mRNA
levels seen in traditional overexpression and knock-out models. The characterization
of the Nkx2-5 haploinsufficiency model should therefore lead to a more
physiologically relevant model of how Nkx2-5 functions in the postnatal heart and
how it affects the pathogenesis of cardiac hypertrophy. The present study identifies a
putative mechanism underlying the Nkx2-5 dosage-dependent modulation of cardiac
hypertrophy using unbiased computational analyses that allow for the identification of
Nkx2-5 dosage-sensitive pathogenic pathways in cardiac hypertrophy in vivo. In
addition, a novel interacting co-regulator of Nkx2-5 and a functionally relevant
downstream target gene were identified as involved in the pathogenesis of cardiac
hypertrophy. Lastly, the present study demonstrates the utility of our computational
approach in identifying novel mechanisms of differential gene regulation in the
pathogenesis of complex diseases.

RESULTS

Nkx2-5+/- mice demonstrate exaggerated cardiac hypertrophy in response to
pathological stimuli
Nkx2-5+/- mice express half-normal levels of Nkx2-5 mRNA and protein 81,83.
The reduction in Nkx2-5 dosage increases the risk of congenital heart defects (CHDs)
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during fetal development. Nkx2-5+/- neonates without CHDs, however, grow into
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healthy adults. Under basal conditions, adult Nkx2-5+/- hearts were indistinguishable
from wild-type hearts in cardiac mass relative to body weight ratio (HW/BW, 4.3±0.1
mg/g in Nkx2-5 WT/sham vs. 4.4±0.1 mg/g in Nkx2-5+/-/sham; P = 0.25; Fig. 3.1a).
The phenotype associated Nkx2-5 haploinsufficiency became apparent only when the
animals were subjected to adverse hypertrophic stimuli. Transverse aortic constriction
(TAC) 27,84 performed on 8-10 week old wild-type mice resulted in an increase in
HW/BW ratio compared with sham-operated littermates 10 days after surgery
(4.3±0.1 mg/g in Nkx2-5 WT/sham vs. 5.5±0.2 mg/g in Nkx2-5 WT/TAC; P = 0.0004;
Fig. 3.1a). After undergoing the same procedure, Nkx2-5+/- mice developed a 73%
greater increase in HW/BW ratio compared with wild-type mice (28±5% increase in
Nkx2-5 WT/TAC vs. 49±6% increase in Nkx2-5+/-/TAC; P = 0.01; Fig. 3.1a),
suggesting that the development of appropriate cardiac hypertrophy in response to
surgical perturbation is an Nkx2-5 dosage-sensitive phenomenon.
A similar Nkx2-5 haploinsufficiency phenotype was observed in the
calcineurin overexpression (CnA-Tg)21 model of cardiac hypertrophy. In
five-week-old mice expressing normal cardiac levels of Nkx2-5, transgenic expression
of calcineurin resulted in a doubling of heart weight in comparison to their
non-transgenic (CnA-Ntg) littermates (HW/BW ratio 4.3±0.1 mg/g in Nkx2-5
WT/CnA-Ntg vs. 9.0±0.2 mg/g in Nkx2-5 WT/CnA-Tg; P =0.0004; Figs. 3.1b and
3.1c, Table 3.1). In Nkx2-5+/- mice, calcineurin overexpression tripled the heart
weight relative to the non-transgenics (HW/BW ratio 4.3±0.1 in Nkx2-5+/-/CnA-Ntg
vs. 13.3±0.5 in Nkx2-5+/-/CnA-Tg; P = 0.0001; Figs. 3.1b and 3.1c, Table 3.1). The
hypertrophic response in Nkx2-5+/-/CnA-Tg mice was therefore twice that of Nkx2-5
WT/CnA-Tg mice (110±5% increase in Nkx2-5 WT/CnA-Tg vs. 210±12% increase in
Nkx2-5+/-/CnA-Tg; P = 0.0001; Figs. 3.1b and 3.1c, Table 3.1). An increase in lung
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weight to body weight ratio, indicative of pulmonary edema, was observed in
Nkx2-5+/-/CnA-Tg animals in association with the enhanced hypertrophic response
(LW/BW ratio 6.0±0.1 mg/g in Nkx2-5 WT/CnA-Tg vs. 6.9±0.1 mg/g in
Nkx2-5+/-/CnA-Tg; P =0.0001; Table 3.1). Similar to the TAC model, there was no
difference in the heart weight to body weight ratio between Nkx2-5+/- and wild-type
hearts under baseline conditions (4.3±0.1 mg/g in Nkx2-5 WT vs. 4.3±0.1 mg/g in
Nkx2-5+/-; P =0.95 Figs. 3.1b and 3.1c, Table 3.1). Additional physiological
parameters of Nkx2-5+/- mice under baseline and hypertrophic conditions are listed in
Table 3.1. The replication of this Nkx2-5 haploinsufficiency phenotype in disparate
cardiac hypertrophy models suggests that Nkx2-5-dependent modification of the
hypertrophic response is independent of the types of hypertrophic stimuli.
The aggravated hypertrophic response to calcineurin overexpression in
Nkx2-5+/- animals compared with wild-type littermates can partially be attributed to
the increases in individual cardiomyocyte size. Under non-hypertrophic conditions,
the cross-sectional area of single cardiomyocytes measured from short-axis heart
sections did not vary between Nkx2-5 WT and Nkx2-5+/- hearts (43.8±1.6 µm2 vs.
42.3±1.2 µm2, respectively; P = 0.46; Fig. 3.1d). In the calcineurin overexpression
model of cardiac hypertrophy, the cardiomyocyte cross-sectional area was increased
by 57±7% in Nkx2-5 WT/CnA-Tg hearts compared with Nkx2-5 WT/CnA-Ntg hearts
(P < 0.0001; Fig. 3.1d), whereas the cardiomyocyte cross-sectional area in
Nkx2-5+/-/CnA-Tg hearts was >1.5 times greater than that in Nkx2-5+/-/CnA-Ntg hearts
(P < 0.0001; Fig. 3.1d). This translates to roughly three times more growth in
cross-sectional area of individual cardiomyocytes as a result of calcineurin
overexpression in Nkx2-5+/- hearts in comparison with Nkx2-5 WT hearts. The
enhanced cardiomyocyte hypertrophy observed in Nkx2-5+/- animals subjected to
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hypertrophic stimuli was further corroborated by whole cell membrane capacitance
recordings, which serve as a proxy measure of cardiomyocyte volume 85.
Cardiomyocytes isolated from Nkx2-5 WT/CnA-Tg hearts exhibited 39±10% more
capacitance than cardiomyocytes from Nkx2-5 WT/CnA-Ntg hearts (132.6±7.5 pF vs.
184.9±7.1 pF, respectively; P < 0.0001; Fig. 3.1e). In Nkx2-5+/-/CnA-Tg hearts, the
capacitance of cardiomyocytes was 60±10% greater than that of cells from
Nkx2-5+/-/CnA-Ntg hearts (130.8±6.2 pF vs. 209.6±9.3 pF, respectively; P < 0.0001;
Fig. 3.1e). Nkx2-5+/-/CnA-Tg cardiomyocytes thus hypertrophied 54% more than cells
from Nkx2-5 WT/CnA-Tg hearts. The supernormal hypertrophic response in Nkx2-5+/mice was additionally associated with impaired survival. Age of death as a result of
calcineurin overexpression 86 in Nkx2-5+/-/CnA-Tg mice was significantly younger
than that in Nkx2-5 WT/CnA-Tg littermates (196±8 days in CnA-Tg vs. 85±16 days in
Nkx2-5+/-/CnA-Tg; P = 0.01; Fig. 3.1f).
A subset of marker genes of cardiac hypertrophy was differentially regulated
as a function of Nkx2-5 dosage under hypertrophic conditions. Quantitative RT-PCR
analysis revealed an enhanced transition from a-myosin heavy chain (Myh6) to

β-myosin heavy chain (Myh7) in Nkx2-5+/- hearts, where Myh7 expression level was
elevated to twice the level seen in Nkx2-5 WT hearts in response to calcineurin
overexpression (P = 0.01; Fig. 3.1g, bottom panels). In contrast, up-regulation of both
ANF and BNP mRNA levels were not significantly altered in Nkx2-5+/- hearts in
comparison to wild-type hearts under hypertrophic conditions (P = 0.44 and 0.16,
respectively; Fig. 3.1g, top panels). Notably, the level of ANF mRNA, but not BNP
mRNA, was decreased in Nkx2-5+/- hearts in comparison to wild-type hearts under
baseline conditions (P = 0.01 and 0.08, respectively), suggesting that Nkx2-5 dosage
sensitivity, in addition to being context-dependent, manifests differently for individual
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genes. In a given cellular environment, such as that in the CnA-Tg heart, Nkx2-5
haploinsufficiency only affects a subset of the molecular pathways involved in the
hypertrophic response.
Transcriptional profiling captures Nkx2-5 dosage-sensitive transcripts in cardiac
hypertrophy
A comprehensive survey of differential gene expression in Nkx2-5+/- and
wild-type mice under basal and hypertrophic conditions would provide a foundation
for identifying gene regulatory pathways that are sensitive to Nkx2-5 dosage in the
context of cardiac hypertrophy. To this end, global gene expression profiling was
carried out in the ventricular myocardium of wild-type, CnA-Tg, Nkx2-5+/-, and
Nkx2-5+/-/CnA-Tg mice using oligonucleotide microarrays. In addition, a comparable
dataset from a TAC experiment 87 obtained through the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) was included in the ensuing computational
analyses to minimize the likelihood of discovering model-specific artifacts.
Supplementary Table S3.1 summarizes the results from the microarray study. The
complete dataset is available for download through the Gene Expression Omnibus via
accession number (pending submission). Of the 12,422 total probe sets represented on
the microarray, 1,885 were significantly different in hearts subjected to TAC in
comparison to sham operated hearts at an ANOVA p-value threshold of 0.05 (Fig.
3.2a). Of these probe sets, 727 were up-regulated and 1,158 were down-regulated. In
the calcineurin overexpression model, significant differences in expression were
detected between CnA-Tg mice and the non-transgenic littermates in 1,216 probe sets.
Among these probe sets, 501 were up-regulated and 715 were down-regulated.
Merging the two datasets produced 342 probe sets with significant differential
expression in both the TAC and calcineurin overexpression models. 126 probe sets
were up-regulated in both TAC- and calcineurin overexpression-induced cardiac
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hypertrophy, including marker genes angiotensin I converting enzyme 1 (Ace) and
BNP. Similarly, 162 probe sets were down-regulated in both models, including
cardiac-specific homeodomain-only transcription regulator Hopx. The Gene Ontology
(GO) biological process terms over-represented in the merged list of probe sets with
significant differential expression in both models of cardiac hypertrophy are listed in
Table 3.2.
The comparison between Nkx2-5+/- and wild-type hearts under baseline
conditions revealed significant differences in the expression of 1,219 probe sets.
Within this group of probe sets, 422 probe sets indicated up-regulation and 797 probe
sets indicated down-regulation. While Nkx2-5+/- adults had no discernable phenotype
differences from wild-type adults under baseline conditions, GO analysis applied to
the expression profiles of non-hypertrophic Nkx2-5+/- and wild-type hearts
nevertheless identified biological process terms associated with the differences in
gene expression at a false discovery rate of 5%, including “protein polymerization”
and “protein biosynthesis”. The complete listing of GO terms associated with
differential gene expression in Nkx2-5+/- hearts under baseline conditions is found in
Table 3.2. Under hypertrophic conditions, comparisons among transcription profiles
from Nkx2-5 WT/CnA-Tg and Nkx2-5+/-/CnA-Tg hearts revealed only 364 probe sets
to be differentially expressed in a significant manner. Exactly one half of the probe
sets in this grouping were up-regulated and the other half were down-regulated. The
comparatively low number of differentially regulated genes suggests that the
hypertrophic response as a result of calcineurin overexpression is not fundamentally
different between Nkx2-5+/- and Nkx2-5 WT mice. GO analysis of these probe sets
points to an enrichment of several biological processes related to heart function, but
none reached statistical significance at a 5% false discovery rate. When the 364 probe
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sets from this comparison were merged with the 342 probe sets differentially
regulated in both TAC and CnA-Tg models, 33 probe sets were found at the
intersection. These represented genes differentially expressed in cardiac hypertrophy
whose expression levels were further modified as a function of Nkx2-5 dosage under
hypertrophic conditions, presumably under the regulation of transcription regulatory
pathways where Nkx2-5 has a dosage-dependent effect in the context of cardiac
hypertrophy.
Computational analysis suggests Nkx2-5 exerts influence on the Egr1 pathway
The results of the transcription profiling experiments suggest that a reduced
Nkx2-5 level affects a limited subset of genes involved in the hypertrophic response.
However, the transcriptional pathways regulating this subset of genes may regulate
other target genes, independent of Nkx2-5 dosage, in the pathogenesis of cardiac
hypertrophy. We therefore devised a computational strategy to screen for transcription
factors driving such regulatory pathways, using the entire complement of gene
expression changes involved in the hypertrophic process and Nkx2-5
haploinsufficiency (Fig. 3.2a). In this analysis, 394 experimentally determined
mammalian transcription factor binding site (TFBS) profiles from the TRANSFAC
database 88 were mapped to the proximal promoter sequences (from -2000bps to
+500bps relative to annotated transcription start site) of each gene. The correlation
between each TFBS’s presence in the proximal promoter with the differential gene
expression in a given mouse model was then evaluated using a ranksum test. TFBS
signatures associated with gene expression changes both in normal transition to
cardiac hypertrophy (in TAC vs. sham and CnA-Tg vs. CnA-Ntg comparisons) and in
the escalation of hypertrophic response as a result of reduced Nkx2-5 dosage (i.e.
Nkx2-5+/-/CnA-Tg vs. Nkx2-5 WT/CnA-Tg comparisons) are indicative of Nkx2-5
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dosage-sensitive transcriptional regulatory pathways active in cardiac hypertrophy.
The comparison between Nkx2-5+/- and wild-type hearts was analyzed separately to
identify Nkx2-5 dosage-sensitive pathways under baseline conditions.
The TFBS screening results are shown in Supplementary Table S3.2, and
summarized in Figure 3.2a. In the comparison between TAC and sham-operated
hearts, 45 unique human and/or mouse TFBS profiles (P < 0.05) associated with
differential gene expression (regardless whether up- or down-regulation) were
identified from a total of 394 TFBS candidates. Similarly, 64 unique TFBS profiles
were found to be associated with expression changes between the CnA-Tg hearts and
the CnA-Ntg hearts. Neither of the two profiles representing Nkx2-5 TFBS was found
in these two lists, suggesting that direct Nkx2-5 binding to the proximal promoters
may not be a dominant mechanism in these models of cardiac hypertrophy. A further
set of 50 unique TFBS profiles was found to be associated with differential gene
expression in the comparison between Nkx2-5 WT/CnA-Tg and Nkx2-5+/-/CnA-Tg
hearts, including one of the TFBS representing Nkx2-5 (M00240, P = 0.02). The
above TFBS lists were merged to reveal three TFBS profiles corresponding to
androgen receptor (Ar), BTB and CNC homolog 2 (Bach2), and early growth
response 1 (Egr1) in the intersection of all three sets (Fig. 3.2a). The presence of these
binding signatures in the proximal promoters is associated with differential gene
expression in both TAC and calcineurin overexpression models and with the Nkx2-5
dosage-dependent modification of gene expression in Nkx2-5+/-/CnA-Tg mice (Fig.
3.2b). Of these transcription factors, Egr1 was singled out for further characterization
in the present study because of its well-defined role in the pathogenesis of cardiac
hypertrophy 89.
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A separate analysis comparing Nkx2-5+/- and Nkx2-5 WT hearts identified 74
unique TFBS profiles that are over-represented in the proximal promoters of
differentially regulated genes in Nkx2-5 haploinsufficiency under baseline conditions
(Fig. 3.2a and Supplementary Table S3.2). One of the two profiles representing
Nkx2-5 was present in this list (M00241, P = 0.05), suggesting that direct Nkx2-5
binding to the promoters may be necessary or sufficient in some of the Nkx2-5 dosage
sensitive gene targets. Other members of this list include important transcription
regulators in the postnatal heart, such as CREB, Hif1, Mef2, NFκb, PPAR, and SRF.
A reduced Nkx2-5 level may affect transcriptional regulation in the target genes via a
modulatory effect on these transcription co-regulators. Notably, Egr1 was not found
in this set. Furthermore, only four unique TFBS profiles were found in the
intersection of the Nkx2-5+/- sets under baseline or hypertrophic conditions
(cumulative P for X ≤ 4 = 0.02, Fig. 3.2a). Taken together, the results from the
Nkx2-5+/- TFBS screens suggest Nkx2-5 haploinsufficiency affects distinct
transcriptional pathways in the heart depending on the pathological context.
The TFBS screen in the hypertrophic hearts led to a hypothetical model where
Nkx2-5 exerts a dosage-dependent effect on Egr1-dependent regulation of
transcription in the pathogenesis of cardiac hypertrophy. Egr1 is an immediate-early
transcription factor activated in cardiac hypertrophy 90,91 and a key mediator of the
hypertrophic process. Saadane et al. demonstrated that homozygous deletion of Egr1
attenuates hypertrophic response to TAC 89. Similarly, animals overexpressing
Egr1-specific suppressor NGFI-A binding protein 1 (Nab1) responded to TAC with
markedly reduced hypertrophy 92. In the calcineurin overexpression model, the
expression level of Egr1 was elevated under hypertrophic conditions (P = 0.02; Fig.
3.2c). The baseline expression and the up-regulation of Egr1 in cardiac hypertrophy
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was unaffected by Nkx2-5 gene dosage (P = 0.51 under baseline conditions and P =
0.37 under hypertrophic conditions; Fig. 3.2c). In comparison, the Nab1 expression
level remained constant in cardiac hypertrophy and was neither a function of Nkx2-5
dosage under baseline nor hypertrophic conditions (Fig. 3.2c). NGFI-A binding
protein 2 (Nab2) is a Nab1 paralog with overlapping functional roles 93. Nab2
transcription is directly regulated by Egr1 47. As measured with both microarrays and
quantitative RT-PCR, Nab2 expression was up-regulated in cardiac hypertrophy and
was further elevated in Nkx2-5+/-/CnA-Tg hearts (CnA-Ntg vs. CnA-Tg, P = 0.02;
Nkx2-5 WT/CnA-Tg vs. Nkx2-5+/-/CnA-Tg, P = 0.03; Fig. 3.2c). Nab2 expression
level, however, was not responsive to Nkx2-5 dosage under baseline conditions (P =
0.86; Fig. 3.2c). Lastly, the Nkx2-5 level was halved, as expected, in Nkx2-5+/- hearts
under both baseline and hypertrophic conditions (P = 0.02 and 0.05, respectively; Fig.
3.2c). Nkx2-5 was not differentially regulated in response to calcineurin
overexpression regardless of Nkx2-5 dosage.
Nkx2-5 physically interacts with Egr1 and Nab1
To establish the role for Nkx2-5 as a co-regulator of Egr1-dependent
transcriptional activation, an in vitro binding assay was carried out to assess potential
protein-protein interactions between Nkx2-5 and Egr1 (Fig. 3.3a). 35S-labeled Egr1
and Egr1 suppressor Nab1 were both shown to bind to Nkx2-5 fused to maltose
binding protein (MBP-Nkx2-5) immobilized on amylose beads. Known interactions
between Nab1 and Egr1 94, and between Gata4 and Nkx2-5 95, were demonstrated as
positive controls. 35S-labeled Gata-4 did not bind to MBP-Egr1, indicating that
specificity was maintained in the assay. Additionally, the Nkx2-5 protein domain
required for the physical interaction between Nkx2-5 and Egr1 was determined with
an in vitro binding assay between MBP-Egr1 and 35S-labeled Nkx2-5 mutants with N51

and C-terminal truncations for known functional domains. As shown in Figure 3.3b,
only those Nkx2-5 fragments containing the homeodomain were able to bind to
MBP-Egr1 in vitro. The homeodomain had previously been shown to be necessary for
the protein-protein interaction between Nkx2-5 and Gata-4 95, despite being primarily
known for its DNA binding activity. As a control, the same set of 35S-labeled Nkx2-5
deletion mutants was tested against MBP-Nkx2-5 to recapitulate results from previous
reports that Nkx2-5 homodimerizes via an interaction between homeodomains 95,96.
The NK2SD domain adjacent to the homeodomain in the C-terminal direction
contributes to the Egr1-Nkx2-5 interaction and Nkx2-5 homodimerization. Nkx2-5
fragment B, which retained the homeodomain but not the NK2SD domain, was able
to bind to both MBP-Egr1 and MBP-Nkx2-5, albeit with reduced affinity.
Nkx2-5, along with Nab1, modulate Egr1-dependent transcriptional activation
Nab2 expression is regulated by Egr1 47 and is sensitive to Nkx2-5 dosage in
the context of calcineurin overexpression-induced cardiac hypertrophy (Fig. 3.2c). To
ascertain the function of Egr1-Nkx2-5 interaction, a transactivation assay was carried
out in C2C12 myoblasts using a luciferase reporter construct driven by the murine
Nab2 proximal promoter (Fig. 3.3c). The introduction of exogenous Egr1 alone
activated the luciferase reporter as expected (P < 0.0001). The addition of Nkx2-5 or
Nab1 had no effect on the baseline activity of the Nab2 promoter, but both were able
to attenuate Egr1-activated reporter activity (P < 0.0001 for both). Egr1-dependent
activation of the Nab2 promoter was maximally suppressed when Nkx2-5 and Nab1
were added to the reaction in combination (P < 0.0001).
Given that the paralogs Nab2 and Nab1 share structural and functional
features and may be partially interchangeable, it is conceivable that Nab2 may itself
exert some effect on Egr1-dependent transcriptional regulation. A follow-up
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transactivation experiment showed that the addition of Nab2 diminished the collective
repressive effect by Nkx2-5 and Nab1 on the Egr1-dependent activation of the Nab2
promoter (Fig. 3.3d). This modulatory effect of Nab2 on Egr1-dependent
transcriptional regulation was dependent on Nab2 concentration (R = 0.88; P =
0.0002). In contrast, the addition of GFP in increasing concentrations had no effect on
the Egr1-dependent activation of the Nab2 promoter (R = -0.22; P = 0.59). These
findings suggest that the transcriptional activation of Nab2 may constitute a feed
forward feature in Egr1-dependent transcriptional regulation in the pathogenesis of
cardiac hypertrophy.
Heterozygous deletion of Nab2 reduced the severity of cardiac hypertrophy in
CnA-Tg mice
The results from the in vitro transactivation experiments predicted that a
decrease in Nab2 expression may impede Egr1-dependent activation of target gene
expression and thus curtail the development of cardiac hypertrophy. We tested this
hypothesis genetically by measuring the extent of cardiac hypertrophy in 35-day old
wild-type, Nab1+/- and Nab2+/- mice overexpressing calcineurin. Under baseline
conditions, the heart weight to body weight ratio in both Nab1+/- and Nab2+/- mice was
not significantly different from with the ratio in their wild-type counterparts (4.8±0.1
mg/g in wild-type vs. 4.7±0.1 mg/g in Nab1+/-; P = 0.72, and vs. 4.7±0.1 mg/g in
Nab2+/-; P = 0.66; Fig. 3.4a). In calcineurin overexpression-induced cardiac
hypertrophy, Nab2+/- mice had a 10.4±3% lower HW/BW ratio in comparison to their
wild-type littermates (11.4±0.3 mg/g in Nab2-WT/CnA-Tg vs. 10.2±0.2 mg/g in
Nab2+/-/CnA-Tg; P = 0.05; Fig. 3.4a). In contrast, the HW/BW ratio in Nab1+/- mice
was not significantly different from that in the wild-type mice under hypertrophic
conditions (11.4±0.3 mg/g in Nab1-WT/CnA-Tg vs. 11.2±0.3 mg/g in
Nab1+/-/CnA-Tg; P = 0.62; Fig. 3.4a). In contrast to Nkx2-5, Nab1 and Nab2
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haploinsufficiency did not lead to an increased lung weight to body weight ratio under
hypertrophic conditions (Fig. 3.4a). Reduced Nab2 dosage also affected mean
survival time in animals with cardiac hypertrophy. When subjected to calcineurin
overexpression-induced hypertrophic stress, Nab2+/- mice demonstrated a prolonged
lifespan relative to their wild-type and Nab1+/- littermates (149±17 days in
Nab2+/-/CnA-Tg vs. 96±12 days in CnA-Tg; P = 0.02, and vs. 124±25 days in
Nab1+/-/CnA-Tg; P = 0.03; Fig. 3.4b).
The expression pattern of the cardiac hypertrophy marker genes ANF and
Myh7, but not BNP, reflected the attenuated hypertrophic response to calcineurin
overexpression in Nab2+/- mice. The up-regulation associated with pathological
cardiac hypertrophy of ANF and Myh7 was blunted in Nab2+/- hearts in comparison to
wild-type hearts in a quantitative RT-PCR analysis (P = 0.01 and 0.05; Fig. 3.4c).
mRNA expression of transcriptional regulators was also differentially regulated to
varying degrees in Nab animals. The elevated Egr1 mRNA level under hypertrophic
conditions did not vary significantly among wild-type, Nab1+/-, and Nab2+/- hearts
(Fig. 3.4d). Similarly, Nkx2-5 and Nab1 expression levels were not responsive to a
reduced dosage of Nab2 or the hypertrophic status of the hearts (Fig. 3.4d). Nab2
expression, however, was up-regulated in cardiac hypertrophy except in Nab2+/- hearts
(CnA-Ntg vs. CnA-Tg, P = 0.02; Nab1+/- vs. Nab1+/-/CnA-Tg, P = 0.01; Nab2+/- vs.
Nab2+/-/CnA-Tg, P = 0.32; Fig. 3.4d). Notably, Nab2 mRNA level was elevated in
Nab1+/- hearts, irrespective of the hearts’ state of hypertrophy (Nab1 WT/CnA-Ntg vs.
Nab1+/-/CnA-Ntg, P = 0.01; Nab1 WT/CnA-Tg vs. Nab1+/-/CnA-Tg, P = 0.05),
suggesting that Nab1-dependent suppression of Nab2 expression is independent of
cardiac hypertrophy. Together, these results point to a context-dependent network of
regulation arising from an intricate interplay among Egr1, Nab1, Nab2, and Nkx2-5.
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DISCUSSION
Nkx2-5 has been extensively studied in fetal heart development but remains
relatively unexplored in adults. In this study, we hypothesized that postnatal Nkx2-5
expression may modulate the pathogenesis of adult heart disease, so we set out to
characterize Nkx2-5+/- mice in the context of cardiac hypertrophy. Nkx2-5+/- mice
express half the normal level of Nkx2-5 mRNA and protein, which presumably
approximates naturally-occurring variations in the normal physiological range of
Nkx2-5 levels more closely than either knockout or overexpression models 97. In the
absence of hypertrophic stress, adult Nkx2-5+/- mice with no CHDs lack a readily
detectable morphological or physiological phenotype. When challenged with
pathologic surgical or genetic stimuli, however, Nkx2-5+/- mice exhibited markedly
enhanced cardiac hypertrophy and poorer survival outcomes than their wild-types
littermates. A set of unbiased computational screens was applied to identify the
mechanisms underlying the Nkx2-5 dosage dependence of hypertrophic responses in
the heart. These analyses combined orthogonal datasets of disparate experimental
origins to generate a mechanistic hypothesis that Nkx2-5 influences the pathogenesis
of cardiac hypertrophy in part by modulating the transcription program regulated by
Egr1, a known mediator of cardiac hypertrophy. Experimental validations in this
study subsequently confirmed that Nkx2-5 physically interacts with Egr1 and its
specific repressor Nab1 to suppress Egr1-dependent transcriptional activation in
cardiac hypertrophy. Whether Nkx2-5-dependent repression of Egr1-dependent
transcription requires physical interaction between Nkx2-5 and DNA in the target
promoter remains an open question. Computational dynamics modeling and further
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experimental investigations are required to reveal the full mechanistic details of the
Nkx2-5-Egr1-Nab1 interaction.
Nab2, a Nab1 paralog, was identified in our screen as a prototypical Nkx2-5
dosage-sensitive target gene under Egr1-dependent transcriptional regulation in the
context of pathological cardiac hypertrophy. In our mouse models, the mRNA
expression level of Nab2 corresponds to the severity of hypertrophic response. A
causal relationship between elevated Nab2 expression and increased cardiac
hypertrophy is supported by a transactivation experiment in which the addition of
Nab2 negated the suppression of Egr1 activity by Nab1 and Nkx2-5 in a
concentration-dependent manner. The effect of Nab2 on the pathogenesis of cardiac
hypertrophy was confirmed genetically in the Nab2+/-/CnA-Tg mice, in which reduced
Nab2 dosage attenuated the hypertrophic response to calcineurin overexpression and
prolonged survival. Egr1-dependent expression of Nab2 may constitute a novel feed
forward mechanism in the pathogenesis of cardiac hypertrophy. However, Nab2 has
also previously been described as a suppressor of Egr1-dependent transcription 98. The
role for Nab2 may therefore be context-dependent, and requires further
characterization. The novel findings from this study are summarized in Figure 3.5.
In the last two decades, over-expression and knockout models have been
established as invaluable tools to study gene function. The expression levels of genes
under study, from nearly zero in null models to up to several thousand times the
wild-type level in overexpression models, departs drastically from what is
physiologically plausible in complex biological processes with multiple layers of
amplification and feedback regulation. The mechanistic insights derived from the
dramatic phenotype in these studies are often qualitative in nature. For instance,
previous studies of Nkx2-5 function in the postnatal heart have linked large deviations
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from the physiological range of Nkx2-5 dosage to the development of cardiomyopathy
34,79,82

. The mechanisms associated with these dramatic phenotypes, however, may not

be directly relevant in the understanding of similar pathologies in human patients.
Modern genomic methods, with ever-greater capacities to generate larger and more
accurate datasets, greatly enhance our ability to identify mechanisms underlying
subtle and previously undetectable phenotypic observations. The modest scale of
differential gene expression involved in governing such regulatory mechanisms belies
their true biological significance. As an example, our study highlights the importance
of precise gene dosage regulation in the upstream regulators Egr1 and Nkx2-5 in the
context of a major disease process. In general, a haploinsufficient animal model that is
indistinguishable from wild-type littermates under normal conditions but that
responds differently under pathological conditions may provide a closer
approximation of real world health and disease than either null models or
overexpression models can deliver.
Lastly, we demonstrated the utility of computational screens as a tool to rapidly
generate testable hypotheses in the laboratory. In this study, computational analyses
were carried out using data generated internally as well as data freely available from
public depositories. The analyses were designed to target a specific class of
hypothetical mechanisms underlying the phenotypic observations manifested in the
Nkx2-5+/- mice. Validation experiments were then performed to inform the subsequent
computational analyses. This iterative and hybrid approach for solving biological
problems may substantially accelerate discoveries and reduce research costs; we were
able to identify novel molecular interactions among transcriptional regulators Egr1,
Nab1, and Nkx2-5, and a functionally relevant downstream target gene, Nab2, despite
the limitations inherent in our computational screen, which was designed to reduce
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the complexity of the analyses. These limitations include: focusing solely on
transcriptionally regulated mechanisms, using stringent criteria to exclude additional
candidate transcriptional regulators and target genes in the TFBS screen, and limiting
the analyses to relatively small regions in the proximal promoters. Given the
ever-increasing volume and quality of data deposited in the public domain, we expect
computational screens to become a routine and ubiquitous part of biomedical research.
Further developments of this computational method are necessary in order to expand
its capabilities and enhance its usability to capitalize on the deluge of data from
modern biomedical studies.

METHODS
Mouse husbandry and genotyping
Nkx2-5 knockout mice were generated by targeted replacement of the entire
coding region with β-galactosidase, as has been previously described 80. The Nkx2-5
strain is maintained in a C57Bl/6 background after >6 backcrosses. Calcineurin
transgenic mice were kindly provided by Dr. Jeff Molkentin, and were maintained by
mating transgenic males to hybrid B6C3F1 females 21. B6C3F1 mice were purchased
from Charles River Laboratories. Nab1 and Nab2 mice 99 were a generous gift from
Dr. Jeff Milbrandt (Washington University School of Medicine, St. Louis, MO). All
protocols conformed with the protocols of the Association for the Assessment and
Accreditation of Laboratory Animal Care and are approved by the animal studies
committee at Washington University School of Medicine.
Transverse aortic constriction model of cardiac hypertrophy
Male mice, aged 8-10 weeks and weighing 22-25 g, were subjected to
transverse aortic banding to induce cardiac hypertrophy, or to a sham operation.
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Pentobarbital (70 mg/kg intraperitoneal) was given for general anesthesia. Each
mouse was positioned supine, and the trachea orally intubated for mechanical
ventilation. After subcutaneous injection of 1% lidocaine (0.1 ml) for local anesthesia,
an incision was made into the left second intercostal space. The aortic arch was
mobilized. The right innominate, left carotid and left subclavian arteries clearly
visualized. A 7-0 silk suture was passed around the transverse aorta between the
innominate and left carotid arteries and tied against a 27-gauge needle to create a
stenotic band. The needle was removed and the chest closed by suturing each layer of
muscle and skin. The mouse remained intubated until resumption of spontaneous
respiration. The animals were allowed to recover under warming lights or on warming
pads until they were fully awake. Sham-operated mice underwent the entire
procedure, including dissection of the aortic arch, but not banding. The duration of the
operation was 20-25 minutes.
Heart weight measurement
Subjects were sacrificed between 35-39 days of age. Measurement of the body
weight, heart weight, lung weight, and tibia length were taken immediately following
dissection.
Cell culture
The C2C12 pre-myocyte cell line was purchased from the ATCC (Manassas,
Virginia) and maintained according to protocol supplied by the vendor
(http://www.atcc.org/). C2C12 cells were transfected using Lipofectamine 2000
(Invitrogen) as per the manufacturer’s instructions. Transfected cells were maintained
for an additional 36 hours following transient transfection before harvest.
RNA extraction
RNA was isolated from the ventricles using Trizol reagent (Invitrogen)
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following the manufacturer’s protocol. Ventricular tissues stored in -80oC were
homogenized in Trizol using the PowerGen 125 homogenizer (Fisher Scientific). The
precipitated RNA was resuspended in 175 µL of RNA lysis buffer from the SV Total
RNA Isolation Kit (Promega, Madison, WI) and purified according to the
manufacturer’s protocol. cDNA was synthesized from 2.5 µg of total RNA using
SuperScript VILO cDNA Synthesis Kit (Invitrogen) according to manufacturer’s
protocol.
Quantitative PCR
Quantitative PCR of cDNA was performed in Mx3005P QPCR System
(Stratagene, Santa Clara, CA) in a 40µL reaction containing iQ SYBR Green
Supermix (Bio-Rad) and PCR primers at a final concentration of 200 nM. Primer
sequences were designed with the PerlPrimer 75 or obtained from PrimerBank 76.
Primers were purchased from Sigma Aldrich or Integrated DNA Technologies
(Coralville, IA). The primer sequences are provided in the supplemental methods.
Relative mRNA expression was determined using the ΔΔ-Ct method and normalized
to Actb.
Expression profiling
Expression profiles of four calcineurin transgenic ventricles (CnA-Tg) and
four non-transgenic ventricles (CnA-Ntg) from five-week-old males were generated
using Affymetrix U74Av2 chips. Expression profiles were scaled with the MAS5.0
software (Affymetrix) and normalized by mean. Expression profiles for FVB mice
subjected to either TAC or sham operations were obtained from the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) 39 under series accession number
GSC1621 87. Differential gene expression was detected using profile ANOVA in
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Spotfire DecisionSite v9.1 (TIBCO, Palo Alto, CA). GO terms over-represented in
differentially expressed genes were identified using Genemerge 74.
Computational analysis
An algorithm modified from Mootha et al. 100 was used to correlate the
presences of mammalian TRANSFAC motifs 88 within the 2.5 kb of proximal
promoters (-2000bps to +500bps relative to annotated transcriptional start sites) to
differential gene expressions. Promoter sequences were extracted from mouse genome
mm8 build based on Refgene annotations and assigned a significance rank derived
from the p-values associated with differential expression in the genes they represent in
a particular expression profile experiment. For each transcription factor binding site
(TFBS) profile, the algorithm first identifies the best instance within each proximal
promoter sequence as previously described 101-103 at every base position, both in the
forward and reverse orientations. A dynamic score threshold is then used to make
presence/absence calls for that TFBS profile within each promoter. The algorithm
thus does not take into account multiple occurrences of weaker TFBSs in a given
promoter. For each TFBS profile, the significance rank associated with presence and
absence calls obtained at every step of bit-score thresholding is evaluated using
ranksum statistics. P-values from the ranksum test were corrected for multiple
hypotheses testing using false discovery rate calculations.
In vitro binding assay
MBP-fusion proteins were expressed in BL21 DE3 competent cells in rich
media containing 0.3mM IPTG. Fusion proteins were released by sonication and
bound to amylose resins. 35S-methionine-labeled Egr1, Nkx2-5, Nab1, and Gata-4
were expressed using T7-coupled reticulocyte lysate system (Promega). Radiolabeled
proteins were incubated in binding buffer with fusion protein bound amylose resins
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for 4 hours in 4oC and electrophoresed by SDS-PAGE. Binding between radiolabeled
proteins and MBP-fusion proteins were detected with autoradiography.
Measurement of whole-cell membrane capacitance
Myocytes were isolated using procedures previously described 104. Briefly,
hearts were mounted on a Langendorf apparatus and perfused in a retrograde direction
through the aorta with a buffer containing 0.8 mg/ml collagenase (type II,
Worthington Biochemical Corp., Lakewood, NJ) 105. Following the perfusion, the LV
apex was dissected, mechanically dispersed and plated on laminin-coated coverslips
and maintained in 5% CO2. Whole-cell recordings were obtained from LV apex
myocytes within 24 hours at room temperature. All voltage-clamp experiments were
performed using an Axopatch 1B patch clamp amplifier (Molecular Devices,
Sunnyvale, CA) and the pCLAMP9 software package (Molecular Devices). Data were
filtered at 5 kHz before storage. Voltage-clamp data were compiled and analysed
using Clampfit v.9.2 (Molecular Devices) and Microsoft Excel. Capacitative
transients recorded in brief ±10 mV voltage steps from the holding potential (−70
mV) were integrated to yield the whole-cell membrane capacitance (Cm).
Measurement of Cardiomyocyte Cross-sectional Areas
Mice were anesthetized with a terminal dose (120 mg/kg) of sodium
pentobarbital via intraperitoneal injection. The sedated animals were perfused with 10
mL of phosphate buffered saline containing 10 mg of heparin (Sigma), followed by
100 mL of 4% paraformaldehyde (PFA) in 0.1 M sodium phosphate buffer (pH 7.2 at
20 °C) in a 20 mL/minute drip using a peristaltic pump. The hearts were then excised
and fixed in 4% PFA for an additional hour. After dehydration in 70% ethanol
overnight, the fixed hearts were embedded, sectioned, and stained with Masson's
trichrome. Microscopy images (20X objective lens) of the heart sections were
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captured using Zeiss Axiovision software. For each heart, 60 cardiomyocytes oriented
perpendicular to the section plane were highlighted using Adobe Photoshop. The
cross-sectional area of each highlighted cells were then determined using NIH
ImageJ.
Cloning and Plasmids
Dr. Jeff Milbrandt (Washington University School of Medicine, St. Louis,
MO) generously provided the following clones: pCB6 HA-Egr1, pCITE Egr1, FCIV
HA-Nab1, CMVneo His-Nab1, and pcDNA3 Nab2. Murine Nkx2-5 in pcDNA3.1 and
pMAL vectors were a gift from Dr. Seigo Izumo. SV40-renilla luciferase in pGL4
was obtained through Promega. Egr1, Nkx2-5 and Nkx2-5 fragments were cloned
from the expression vectors into pMALc2 vector (NEB) for in vitro expression of
maltose binding protein (MBP) fusion proteins. Primers used for cloning Nkx2-5
fragments are listed in Supplementary Table S3.3. Nab2 promoter from -2000 bps to
+500 bps was cloned from genomic DNA of a C57Bl/6 donor by PCR using primers
listed in Supplementary Table S3.3. PCR product was cloned into pCRII cloning
vector using the PCRII TOPO TA Cloning Kit (Invitrogen). The Nab2 promoter was
subsequently sub-cloned into a pGL3 luciferase vector (Promega) at the unique XhoI
and HindIII site. Clones in ‘plus’ orientation were screened by restriction digestions
and sequence verified.
Transactivation Assay
C2C12 pre-myocytes cultured in 24 well plates were transfected with 0.4mg of
Nab2 luciferase reporter construct and 0.01mg of SV40 renilla luciferase construct,
with or without activators Egr1, Nkx2-5, and Nab1. The transactivation assay was
carried out immediately following cell harvest using the Dual-Luciferase Reporter
Assay System (Promega) following the manufacturer’s instructions. Nab2 luciferase
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activity was measured in 10 seconds intervals in a Leader 50i luminometer
(Gen-Probe, San Diego, CA) serially. Nab2 luciferase activity measurements were
normalized to SV40-driven renilla luciferase readings measured in the same reaction.
Statistics
Two-tailed student’s t-tests were used to access the significance level in all
pair-wise comparisons. The significance levels of Venn logic were calculated using
cumulative probability assuming hypergeometric distribution. All errors were
reported as ± s.e.m.
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FIGURES

*
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Figure 3.1: Nkx2-5 haploinsufficiency led to the exacerbated cardiac hypertrophy and
poor prognosis in response to pathological hypertrophic stimuli. (a) Cardiac
hypertrophy developed following transverse aortic constriction was enhanced In
Nkx2-5 haploinsufficient (Nkx2-5+/-) mice in comparison to wild-type (WT)
littermates (p=0.011). Nkx2-5 haploinsufficiency has no appreciable phenotype in
sham-operated mice. (b) The extent of cardiac hypertrophy developed following the
overexpression of calcineurin transgene was roughly doubled in Nkx2-5+/-/CnA-Tg
hearts in comparison to CnA-Tg hearts (p<0.001). Nkx2-5 WT and Nkx2-5+/- hearts
showed no difference in terms of cardiac mass under baseline conditions. n = 6-18 per
genotype group. (c) Nkx2-5+/-/CnA-Tg hearts showed dramatic hypertrophy in
comparison to wild-type hearts as a result of calcineurin overexpression at 35 days of
age (bottom row). Nkx2-5 WT and Nkx2-5+/- hearts were indistinguishable
morphologically under baseline conditions (top row). The white scale bar indicates
10mm. (d) Cross-sectional area of ventricular cardiomyocytes was greater in the
Nkx2-5+/-/CnA-Tg hearts in comparison to CnA-Tg hearts. Nkx2-5 dosage had no
effect on the cross-sectional areas in non-transgenic (CnA-Ntg) cardiomyocytes. n =
60 per group. (e) Whole cell membrane capacitance was increased by 39% and 60%,
respectively, in the CnA-Tg and Nkx2-5+/-/CnA-Tg hearts in comparison to their
non-transgenic counterparts (p=0.038). Nkx2-5 dosage had no effect on the whole cell
membrane capacitance values in non-transgenic (CnA-Ntg) cardiomyocytes. n = 60
per group. (f) CnA-Tg mice die prematurely due to heart failure (median = 196 days,
solid tracing). The median survival time for Nkx2-5+/-/CnA-Tg mice was reduced to 72
days for the male (n = 4, dark dashed tracing, p=0.005). (g) Quantitative RT-PCR
result showing mRNA expression level for selected cardiac hypertrophy markers
differentially regulated in calcineurin overexpression induced cardiac hypertrophy
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and Nkx2-5 haploinsufficiency (n = 4). For all panels, error bars indicate s.e.m. (*, P <
0.05).

67

Nkx2-5 WT

Nkx2-5

+/-

CnA-Ntg

CnA-Tg

CnA-Ntg

CnA-Tg

HW/BW

4.27±0.08

8.95±0.22†

4.28±0.06

13.27±0.47*‡

LW/BW

6.15±0.06

5.95±0.14

6.26±0.11

6.88±0.06*‡

EDD

3.16±0.15

4.15±0.17†

3.12±0.10

4.21±0.14*

ESD

1.41±0.19

2.72±0.27†

1.67±0.15

2.71±0.21*

LVPW

0.65±0.03

0.82±0.02†

0.67±0.03

0.94±0.03*‡

FS

55.83±4.08

35.17±4.41†

46.89±3.45

36.17±3.39

HR

527.50±25.88

445.17±36.11

485.67±32.67

439.17±53.94

n

6

6

7

6

Table 3.1: Physiologic parameters in wild-type (WT) and Nkx2-5+/- mice under
baseline (CnA-Ntg) or hypertrophic (CnA-Tg) conditions. HW/BW: heart weight to
body weight ratio (mg/g); LW/BW: heart weight to body weight ratio (mg/g); EDD:
end-diastolic diameter (mm); ESD: end-systolic diameter (mm); LVPW: left
ventricular posterior wall thickness (mm); FS: fractional shortening (%); HR: heart
rate (min-1). †: P < 0.05 in the Nkx2-5 WT/CnA-Ntg vs. Nkx2-5 WT/CnA-Tg
comparisons; ‡: < 0.05 in the Nkx2-5 WT/CnA-Tg vs. Nkx2-5+/-/CnA-Tg comparisons;
*: < 0.05 in the Nkx2-5+/-/CnA-Ntg vs. Nkx2-5+/-/CnA-Tg comparisons.
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Figure 3.2: Egr1 was identified in a computational screen as an Nkx2-5
dosage-sensitive transcriptional regulator in the pathogenesis of cardiac hypertrophy.
(a) A schematic of our computational strategy and results. Left: the numbers of probe
sets up- and down-regulated in each of the comparisons are given next to the Venn
diagrams adjacent to the model names. Center: the proximal promoter sequences for
every gene represented on the microarray were curated and ordered based on the
significance level of their differential regulation in each comparison. A ranksum test
was then used to determine the correlation between the presence of a particular
transcription factor binding site (TFBS) in the proximal promoters and differential
gene expression. Right: The numbers of TFBS whose presence in the proximal
promoters was associated with differential gene regulation at a false discovery rate of
5% are given for each comparison in the Venn diagram. Egr1 was found in the
intersection of all three TFBS lists. (b) The presence of Egr1 TFBS in the proximal
promoters was associated with differential gene expression in all three comparisons
(see Fig. 3.2a). The ranks of each gene, or probe set, ordered by the significance level
of its differential expression in a given comparison, are represented on the horizontal
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axis, with the most significant towards the left of the graph. The red tracings reflect
the negative log of each gene’s ANOVA p-value in a given comparison. Each black
hatch represents five successive Egr1 TFBS positive proximal promoters and is
positioned at the centroid of the five promoters on x-axis. The p-values of the
correlations are 0.001 (ranked 11th), 0.0001 (ranked 1st), and 0.002, (ranked 16th) in
TAC, CnA-Tg, and Nkx2-5+/-/CnA-Tg models, respectively. (c) Quantitative RT-PCR
results showing ventricular mRNA expression patterns of Egr1, Nab1, Nab2, and
Nkx2-5 in calcineurin overexpression-induced cardiac hypertrophy and Nkx2-5
haploinsufficiency. Error bars indicate s.e.m. (*, P < 0.05, n = 4).

70

Baseline vs. TAC and CnA-Tg
Population

Study

GO Accession

fraction

fraction

Description

0006817

53/7013

10/100

phosphate transport

1.6E-07

0007155

266/7013

17/100

cell adhesion

4.9E-06

0014037

3/7013

2/100

Schwann cell differentiation

1.2E-02

0030162

4/7013

2/100

regulation of proteolysis

1.8E-02

0001558

45/7013

4/100

regulation of cell growth

4.4E-02

P-value

Nkx2-5 WT vs. Nkx2-5+/Population

Study

GO Accession

fraction

fraction

Description

0008152

254/7013

17/122

metabolism

9.0E-05

0006099

20/7013

5/122

tricarboxylic acid cycle

5.3E-04

0006631

44/7013

5/122

fatty acid metabolism

8.8E-03

0006633

24/7013

4/122

fatty acid biosynthesis

1.0E-02

0019439

3/7013

2/122

aromatic compound catabolism

1.0E-02

P-value

peroxisome organization and
0007031

10/7013

3/122

biogenesis

1.1E-02

0001662

4/7013

2/122

behavioral fear response

1.4E-02

0008542

5/7013

2/122

visual learning

2.1E-02

0001676

6/7013

2/122

long-chain fatty acid metabolism

2.7E-02

0006725

7/7013

2/122

aromatic compound metabolism

3.1E-02

branched chain family amino acid
0009083

7/7013

2/122

catabolism

3.4E-02

0009636

9/7013

2/122

response to toxin

3.8E-02

0042593

9/7013

2/122

glucose homeostasis

4.1E-02

0006629

103/7013

6/122

lipid metabolism

4.2E-02

0006637

9/7013

2/122

acyl-CoA metabolism

4.4E-02

0006749

10/7013

2/122

glutathione metabolism

4.4E-02

Table 3.2: Gene Ontology (GO) terms associated with differential gene expression in
cardiac hypertrophy and Nkx2-5 haploinsufficiency.
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Figure 3.3: Nkx2-5 interacts with Egr1 and Nab1 to modulate Egr1-dependent
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transcriptional activation in the proximal promoter of candidate target gene Nab2. (a)
In vitro binding assay showing 35S-labeled Egr1 physically interacting with
immobilized full length Nkx2-5 (lane 1) and a C-terminal fragment of Nkx2-5
(fragment F, aa137-318, lane 3) but not a N-terminal fragment (fragment A, aa1-136).
35

S-labeled Nab1 also physically interacted with MBP-Nkx2-5 (lane 6). Previously

described Egr1- Nab1 (lane 5) and Nkx2-5-Gata-4 (lane 9) interactions were included
as controls. (b) 35S-labeled truncation fragments of Nkx2-5 were tested for interaction
with MBP-Egr1 or MBP-Nkx2-5 to determine the Nkx2-5 protein domain involved in
these protein-protein interactions. The fragments are shown as grey arrows below a
schematic drawing of Nkx2-5 structure. The darker shade indicates Nkx2-5 fragments
in which MBP-Egr1 binding activity is preserved. The 35S signals retained from
positive interactions to MBP-Egr1 and MBP-Nkx2-5 were normalized to the input
signals and shown on the right. (c) A transactivation assay demonstrating the effect of
Nab1 and Nkx2-5 on Egr1-dependent activation of the Nab2 proximal promoter
(-2000-+500 relative to annotated transcriptional start site). The addition of Egr1
alone activated the Nab2 promoter. Nkx2-5 and Nab1 both had a suppressive effect on
Egr1-dependent transcriptional activation of the Nab2 promoter. (d) A transactivation
assay demonstrating the effect of Nab2 on the Nab1/Nkx2-5-dependent suppression of
Egr1-dependent activation of the Nab2 promoter. The addition of an increasing
concentration of Nab2 reduced the suppressive effect of Nab1 and Nkx2-5 on
Egr1-dependent activation of the Nab2 promoter, but the addition of an increasing
concentration of GFP did not. For all panels, error bars indicate s.e.m. (*, P < 0.05
compared with luciferase activity when only Egr1 was present, unless otherwise
indicated, n = 4).
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Figure 3.4: Reduced Nab2 gene dosage modifies the phenotype in the CnA-Tg model
74

of cardiac hypertrophy. (a) Calcineurin overexpression-induced cardiac hypertrophy
was attenuated in Nab2+/- mice. (P = 0.05, n = 6-11). Nab1 or Nab2
haploinsufficiency did not affect the cardiac mass under baseline conditions. Lung
weight was unaffected by changes in Nab1 or Nab2 level under baseline or
hypertrophic conditions. (b) A Kaplan-Meier plot showing improved survival in
Nab2+/- animals compared with wild-type (WT) and Nab1+/- littermates under
hypertrophic conditions (P = 0.02 and 0.03, respectively, n = 6-11). (c) Quantitative
RT-PCR results showing the ventricular mRNA expression patterns of cardiac
hypertrophy markers ANF, BNP, Myh6, and Myh7 under baseline or hypertrophic
conditions in WT, Nab1+/-, and Nab2+/- animals. Error bars indicate s.e.m. (*, P < 0.05,
n = 4). (d) Quantitative RT-PCR results showing the ventricular mRNA expression
patterns of transcriptional regulators Egr1, Nab1, Nab2, and Nkx2-5 under baseline or
hypertrophic conditions in WT, Nab1+/-, and Nab2+/- animals. Error bars indicate
s.e.m. (*, P < 0.05; ns, not significant; n = 4).
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Figure 3.5: A model outlining the proposed mechanism underlying the phenotype of
Nkx2-5+/- and Nab2+/- animals in pathological cardiac hypertrophy.

Supplementary Table S3.1: (Attached) Differential gene expression in mouse
models of cardiac hypertrophy and Nkx2-5 haploinsufficiency. Separate tables
corresponding to the Venn diagrams shown in Figure 3.2a (left) are provided.
Supplementary Table S3.2: (Attached) Results from the TFBS screens. Separate
tables corresponding to the Venn diagrams shown in Figure 3.2a (right) are provided.
The ‘TF_ACCESSION’, ‘TF_ID’, and ‘TF_NAME’ fields contain the official
accession numbers, IDs, and names for each TFBS in the TRANSFAC dataset.
‘Maximum Score’ field contains the best possible scores for each TFBS under the
scoring model used. The ‘Best Z Score’, ‘PV’, and ‘Rank’ fields contain the ranksum
z-scores, the corresponding p-values, and the ranks (lower is more significant) for
each TFBS within the models compared, using the optimal scoring threshold recorded
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in the ‘Scoring Threshold’ field to determine the presence of the particular TFBS in
the proximal promoters. Repeated TFBS entries with higher ranks were removed to
render the TFBS records unique.
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qRT-PCR:
Probes

Forward/Reverse

Nkx2-5

AGTGCTCTCCTGCTTTCC/CTTTGTCCAGCTCCACTG

Actb

GCGTGACATCAAAGAGAAGC/AGGATTCCATACCCAAGAAGG

Nppa

GCAGAGACAGCAAACATCAG/TCTAGCAGGTTCTTGAAATCCA

Nppb

CAGAGACAGCTCTTGAAGGA/AACAACTTCAGTGCGTTACAG

Egr1

TCGGCTCCTTTCCTCACTCA/CTCATAGGGTTGTTCGCTCGG

Nab1

CTGATGGACAAGGAGAAAGAC/TTTAGAATCCCAAGGCTCTC

Myh6

GCCCAGTACCTCCGAAAGTC/GCCTTAACATACTCCTCCTTGTC

Myh7

ACTGTCAACACTAAGAGGGTCA/TTGGATGATTTGATCTTCCAGGG

Nab2

TGGCAGAGGGGATAACACAC/CGTTGCAGGACCCGATACAG

Genotyping:
Nab1 Genotype WT For

GGTCCATGTATTTTGCATATTTCTTATTT

Nab1 Genotype KO For

GCATCACAAATTTCACAAATAAAGCATTTT

Nab1 Genotype Com Rev

CACAGACTTGATGTGATTTCAGTCATTCTT

Nab2 Genotype 9598

CTTCTCGAGCACTGCCCGCCTTTTCTC

Nab2 Genotype 9599

GGAATTCGCCATGGCACTGCCTC

Nab2 Genotype 9600

ACGGGCGTCCGCGTCGTTGTTTG

Nab2 Genotype 9601

CTTCGCCCAATAGCAGCCAGTCC

Nkx2-5 PB Forward?

GACAAAGCCGAGACGGATGG

Nkx2-5 PB Reverse?

CTGTCGCTTGCACTTGTAGC

CnA genotyping forward
CnA genotyping reverse

Nab2 Cloning:
Nab2 Genomic PCR -2097

AGCCCCGCGCTAACAGGTTTAC

Nab2 Genomic PCR +515

TCTTCTCCCCCTGCTCCAACATC

Nab2 Promoter Cloning For

AAAACTCGAGTTCTAACATTCAAACTAACGGCTCGGCGCGG

Nab2 Promoter Cloning Rev

AAAAAAGCTTGAGTGGCGACAACTTCTCTCCAAGTTCGAGG

Nkx2-5 Fragments
Csx pcDNA Cloning 1F

AAA-GAATTC-GACACC-ATG-ttccccagccctgcgctcacacccac

Csx pcDNA Cloning 137F

AAA-GAATTC-GACACC-ATG-cgacggaagccacgcgtgctcttctcgcagg

Csx pcDNA Cloning 208F

AAA-GAATTC-GACACC-ATG-caggaccagactctggagcttctggggccg

Csx pcDNA Cloning 251F

AAA-GAATTC-GACACC-ATG-taccccagctacggcggcgcggcctgcag
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Csx pcDNA Cloning 136R

AAATCTAGACTACCGCCGTGCGCGTGGTCTCTCGG

Csx pcDNA Cloning 207R

AAATCTAGACTACGGCGGCCCCAGAAGCTCCAGAGTC

Csx pcDNA Cloning 255R

AAATCTAGACTAGGGGTAGGCGTTGTAGCCATAGGCA

Csx pcDNA Cloning 313R

AAATCTAGACTAGTGCAGCGTGGAGACGCCCGAATTG

Csx pcDNA Cloning 318R

AAATCTAGACTACCAGGCTCGGATGCCGTGCAGCGTG

Supplementary Table S3.3: A list of primers used in the genotyping, cloning, and
quantitative RT-PCR experiments described in the present study.
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Chapter 4. Summary and Conclusion
Transcription is a fundamental mechanism underlying the causality of an
organism’s inherent genotype and its observed phenotype. Thus, study of
transcriptional regulation forms the basis of modern molecular genetics. In
development, tissue destined to make up each organ must express an appropriate set
of genes which ultimately actualizes its form and function. This process is highly
regulated through an intricate interplay between transcription factors and their target
sequences in the genomic DNA. Transcriptional regulation is dynamic. Network of
signaling proteins forms pathways directing the transcription factors to differentially
regulate their target genes in response to normal or pathologic extrinsic stimuli.
Understanding transcriptional regulation of a biological process is a critical step to
gain the ability to modify the process and influence the outcome. As such, biomedical
research efforts of the past few decades placed a major emphasis on prediction and
linkage of novel transcriptional regulatory pathways to phenotype changes in
development and disease. The advancement of high-throughput experimental
methodology and computational biology offers unprecedented speed and ease to
capture undiscovered regulatory pathways for detailed study in the context of specific
biological processes. The work presented in this dissertation provides a computational
framework to analyze datasets generated by high-throughput experimental methods.

The analytical framework described here consists of two complementary
approaches based on rank-sum statistics to identify such pathways. The first approach
enables meta-analysis of large microarray datasets encompassing thousands of
samples to predict tissue-specific gene expression patterns. Each gene’s expression
pattern is summarized as a series of expression ranks in various tissues, thus making
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tests of correlation to a phenotype of interest possible. This part of the analytical
framework was applied to study various aspects of adipose tissue biology and obesity.
The second approach correlates transcription factors to a transition in phenotype by
detecting improbable relative abundance of specific transcription factor binding sites
in the proximal promoters of genes differentially regulated in response to such
transition. I applied this approach to study the modification of cardiac hypertrophy
phenotype in mouse models by cardiac-specific transcription factor Nkx2-5. The
computational methods set forth herein establish a flexible and unbiased mean of
orthogonal data integration and rapid hypothesis generation.

In addition to the development of computational methods, I have identified and
characterized novel transcriptional regulators each of which represents a potential
point of therapeutic intervention in major human diseases. In the preliminary study
leading to the part of my thesis research pertaining to the induction of brown fat
phenotype in WAT, my analytical framework furnished a focused and testable
hypothesis that nuclear receptor Esrrg and a host of putative Esrrg targets share
similar tissue-specific expression pattern as BAT master regulator Prdm16. This was
achieved using only open-access public data at nearly no cost to our laboratory. In the
validation experiments, I showed that Esrrg indeed functions to up-regulate BAT
markers such as Ucp1 in adipocyte cell culture system. Specific inhibition of Esrrg
with 4-OHT, an activated tamoxifen derivative, prevented the up-regulation of Ucp1
in the WAT of mice subjected to long-term cold temperature exposure. I further
identified Srebp1c as a co-regulator of Esrrg. Transfection of Srebp1c in Esrrg-rich
myoblast cell line C2C12 results in strong up-regulation of BAT marker Ucp1. The
addition of 4-OHT or co-transfection with vectors expressing Esrrg-targeting shRNA
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in the same cell culture model attenuated Srebp1c-dependent Ucp1 up-regulation.
Targeted delivery of Esrrg agonist may represent an attractive therapeutic strategy
given the high interest in novel pharmaceutical treatments of obesity.

My thesis research also made progress towards a more complete understanding
of the pathogenic process in cardiac hypertrophy. By combining orthogonal datasets
including expression profiles from multiple mouse models of cardiac hypertrophy,
genomic sequences, and experimentally determined transcription factor profiles, my
computational method predicted that the Egr1 pathway may be sensitive to Nkx2-5
dosage which would account for the exacerbated cardiac hypertrophic response to
detrimental stimuli observed in the Nkx2-5 haploinsufficient mice. This hypothesis
was validated in vitro where a novel protein-protein interaction between Nkx2-5 and
Egr1 was demonstrated. The functional consequence of this interaction appears to be
the suppression of Egr1-dependent transcriptional activation. A target of this
regulation is Nab2. Nab2 is a paralog of Egr1-specific repressor Nab1. Egr1-driven
expression of Nab2 can interfere with Nab1-dependent suppression of Egr1, thus
forming a feed forward loop. Indeed, male mice haploinsufficient for Nab2 have
smaller hearts and improved survival in a yearlong validation study in vivo. While in
no way challenging the value and validity of traditional gain- and loss-of function
animal studies, my results suggest that small deviations in gene dosage can in fact
lead to dramatic phenotypic differences even in complex multigenic diseases. Another
unexpected, yet intriguing, discovery was the sexually dimorphic response to Nab
gene dosage in the context of cardiac hypertrophy. While the male Nab mice behaved
consistently with the predictions in silico and the results in vitro, the females did not.
My results suggest that Nab2 is expressed at a higher level in the males at baseline
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and contributes more towards the development of cardiac hypertrophy in the males
compared to females. This may represent a first instance of sexually dimorphic
mechanism at the level of transcriptional regulation in cardiac hypertrophy that does
not involve sex hormones.
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Chapter 5. Future Directions
Several studies making novel use of tissue-specific gene lists are ongoing to
accelerate discoveries and are generating a significant interest in this resource. In
obesity, the white adipose tissue up-regulates specific adipokines, cytokines, and
chemokines 12. Using ob mice as a model of obesity 106, I was able to correlate the
differential regulation of chemokines in the obese WAT to specific immune cell
targets by including the chemokine-receptor pairing information in the analysis. The
results from this study may enhance our understanding of the cell-cell communication
important in the pathogenesis of obesity. The interception of such communication
may lead to a novel strategy to curtail the development of obesity.

Another on-going project is the linkage analysis of atrial septal defect (ASD) in
Nkx2-5+/- mice. Using microsatellite markers in a GWAS study, Julia Honold et al.
were able to identify an allele that co-segregates with the development of ASD in
Nkx2-5+/- neonates. 31 A typical allele resolved by microsatellite markers contains
hundreds of known genes. Fine mapping, which is both cost and labor intensive, is
therefore necessary to narrow down the causal gene within the genomic region. In a
novel approach to this problem, we used the cardiac-specific gene list to prioritize
candidate genes assuming that genes with highly restricted expression would likely be
functionally important in the tissues they express in. We are currently focusing on
sarcospan as a candidate modifier gene of Nkx2-5 in the context of ASD development.
Sarcospan expression is highly specific in the heart, and plays a role in the
development of muscular dystrophy 107,108. The preliminary results are near significant
and encouraging. If successful, this approach can be adopted in any GWAS study
where hypothesis can be reasonably made on the tissue-specificity of the causal gene.
84

Tissue specific gene lists can be useful in a scenario where one tissue takes on
the function of another in a well-defined manner as exemplified in WAT to BAT
transdifferentiation. Bielinska et al. have described development of adrenal tumors
that produce sex hormones in gonadectomized mice 109. Transcription factor Gata4 is
involved in the tumor development but the precise mechanism of tumorigenesis is not
known. RNA-seq experiment to survey gene expression in the adrenal tumors is
planned to gain further understanding of the tumorigenic process. The gonad-specific
gene list can be applied here to facilitate the interpretation of the differential gene
regulation associated with tumor transformation and sex hormone production.

At the conclusion of the study described in Chapter 2, several topics were left
unexplored and warrant further investigation. Our understanding of how promoter
sequences encode instruction for tissue-specific expression is incomplete. At one
point in my thesis research, I had attempted to correlate global tissue-specific gene
expression to combinations of TFBSs found over-represented in the promoters of a
training set of known tissue-specific genes. This approach had a limited yield since
the TFBS input was not reliable. Revisiting this problem using data from the latest
methods such as ChIP-seq may boost probability of success. A few issues also remain
unresolved regarding the validation experiments. The study did not make clear
whether the forced expression of BAT markers had any functional consequence in
vitro and in vivo. Further metabolic and gene expression studies could help
determining what the white adipose tissue expressing BAT markers actually represent
functionally. Additionally, how the Esrrg pathway relates to the Prdm16 pathway is
not known. Prdm16 expression was marginally up-regulated in the WAT following
85

exposure to cold and was not diminished in response to addition of 4-OHT. Prdm16
may be necessary but insufficient in cold-induced BAT gene activation in WAT.
Direct testing of Prdm16 in this context is needed to better define its functional
relation to Esrrg.

My work on Nkx2-5 haploinsufficiency described in Chapter 3 similarly opens
opportunities for further study. While my results point to a model where Nkx2-5
haploinsufficiency modifies target gene expressions through changes in the dynamics
of physical interaction between Nkx2-5 and transcriptional co-regulators, they do not
rule out a mechanism where Nkx2-5-DNA interactions are altered directly to cause
differential gene regulation. To this end, I had unsuccessfully analyzed the proximal
promoter sequences in differentially regulated genes in the Nkx2-5+/- hearts compared
to wild-type hearts under non-hypertrophic conditions. Nkx2-5 ChIP data and more
accurate and comprehensive surveying of global mRNA expression have since
become available which may facilitate the discovery of promoter/enhancer sequence
elements that specify Nkx2-5 dosage sensitivity.

The conclusions from the series of animal studies carried out for this work may
be bolstered by additional experiments. Due to the availability of mice and time and
space constraints I was not able to directly characterize mice with reduced Egr1
expression levels in the context of calcineurin overexpression induced cardiac
hypertrophy. Similarly, how the Nab haploinsufficiency interacts with Nkx2-5
haploinsufficiency in the context of cardiac hypertrophy has not been investigated in
full. I hypothesize that, at least in the males, Nab2 haploinsufficiency may attenuate
the enhanced hypertrophic response in the Nkx2-5+/-/CnA-Tg mice. Mice needed to
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test this hypothesis currently are being bred in the Jay lab. In addition, the Nab
haploinsufficient mice may be further characterized in a different model of cardiac
hypertrophy such as the TAC model. Additional phenotyping experiments such as
echocardiography and electrophysiology studies may be useful in establishing the
functional consequences of Nab haploinsufficiency in the context of cardiac
hypertrophy.
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